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FOREWORD
The release of animals, whether it be for translocation from one wild population to
another, the introduction of captive-borne animals into a natural wild population, or the
return of rehabilitated animals into the wild after varying periods of time in captivity, have
become commonplace in recent years. Such releases are not without consequences and
must be considered in terms of the level of risk of disease transfer. Once ignored and
little understood, it is now widely recognised that these releases must not be regarded as
consisting of just a single animal, but rather of a package of organisms, including those
viruses, bacteria, protozoa, helminths and arthropods, which any single animal may
habour. Any of these organisms may become pathogenic under stressful situations,
affecting not only the released animal but equally important, other animals, including
humans, in the release environment.
In an effort to address the disease considerations of wild animal releases, Michael
Woodford has assembled information regarding quarantine, screening procedures and
treatment/vaccination suggestions for mammals, birds, reptiles, amphibians and fish.
These protocols are comprehensive and represent the ideal, given our current level of
understanding of the potential risks of the various organisms that may be carried by any
single animal. We are reminded that once an animal has been released into the wild, it is
rarely, if ever, possible to recover that animal or the potential pathogens it may be
carrying. Thus it is incumbent upon all who are charged with the release of wildlife to
follow stringent guidelines that will help to ensure the merit and wisdom of releasing such
wildlife.
“Quarantine and Health Screening Protocols for Wildlife Prior to Translocation to Release
into the Wild” is an excellent reference source and will enable the veterinarian to make
rational decisions regarding release based on currently available science. Michael
Woodford and his fellow contributors are to be congratulated for their thoughtful approach
to this subject.

Wilbur B. Amand, VMD
Executive Director
American Association of Zoo Veterinarians
Immediate Past President of the World Association of Wildlife Veterinarians
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QUARANTINE AND HEALTH SCREENING PROTOCOLS FOR WILDLIFE
PRIOR TO TRANSLOCATION AND RELEASE INTO THE WILD

1.

INTRODUCTION

In recent years the translocation and release into the wild of wild-caught and captive-bred
wild animals (mammals, birds, reptiles, amphibians and fish) has become a common
1
practice, ostensibly for rehabilitation or conservation purposes. These wild animals
comprise many varied taxa and the objectives of translocation and release may include:
(1) reintroducing a species that has become extinct in its natural range;
(2) restocking or reinforcing a population which has become depleted; and
(3) rehabilitating wild animals and birds which have been illegally captured and
subsequently confiscated by Customs or national wildlife authorities. Welfare
organisations also receive sick and injured wild animals from the public and some of
these can be restored to health and released.
Each year very large numbers of wild animals also undergo both local and transcontinental
translocation for release in new and strange habitats for sporting purposes. For example,
hares (Lepus europaeus) are regularly translocated from Argentina to France and from
2
Eastern Europe to Italy.
It is now widely recognised by wildlife veterinarians that every wild creature that is the
subject of a translocation or rehabilitation release must not be regarded as just a single
animal but rather as a “package” containing an assortment of potentially dangerous viruses,
bacteria, protozoa, helminths and arthropods, any of which may become pathogenic in a
3
new situation, involving stressed individuals in a changed environment.
Translocation of an animal and its potential pathogens, over even a short distance, may
threaten the health of indigenous wild species, domestic livestock or humans. In addition,
the effects of stress on the immune system of animals while held in captivity pending
translocation and release may increase this risk, unless well managed. However, the risk
can be assessed in advance and substantially reduced if timely veterinary precautions are
taken.
These precautions will include: a clinical evaluation of the health status of the source
animals and those at the translocation destination, a period of quarantine, appropriate health
screening procedures, a consideration of the legal and veterinary restrictions on
translocation of wild animals to and from certain geographic areas or populations, and when
necessary, pre-release treatment and immunisation. It should be remembered that not only
should the translocated animals undergo health screening but so also should the indigenous
4, 5
wildlife in the reception area.
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Translocation and Reintroduction Policy
The reader is referred at an early stage to two important policy statements and guidelines.
The first was prepared by the IUCN Species Survival Commission in collaboration with the
Commission on Ecology and the Commission on Environmental Policy, Law and
2
Administration.
This document, published in 1987, sets out IUCN’s position on the
Translocation of Living Organisms, covering introductions, re-introductions and re-stocking.
The second document, entitled IUCN Guidelines for Re-introductions, has been prepared by
1
the IUCN/SSC Re-introduction Specialist Group in 1998, and consists of specific policy
guidelines designed to ensure that translocations and re-introductions achieve their intended
conservation benefit and are not responsible for any adverse consequences.
Both these important Policy Statements should be carefully studied before any living
organism is translocated for whatever purpose.
Note: It must always be remembered that once a wild animal has been released into
the wild it is very rarely possible to recover it or the potential pathogens it may have
carried.

Evaluation of the health status of the animals and their source population
It is recommended that the attending veterinarian should obtain and review all available
information concerning the health of the animals to be translocated, and where possible,
that of their source population. Sources of such information could include published
literature, unpublished necropsy and diagnostic records of local national veterinary
laboratories, national departments of agriculture and colleges of veterinary medicine.
Disease surveillance protocols and information on the occurrence of domestic animal (and
some wildlife) diseases can be obtained from the annual FAO Animal Health Yearbook,
the OIE 'Animal Health in 1997' publication and for Europe, from Faune Sauvage
d'Europe (Informations Techniques des Services Veterinaires), and from Bulletin
d’Information sur la Pathologie des Animaux Sauvages en France (BIPAS). Information
on wildlife diseases can be obtained from a variety of sources including national or regional
wildlife authorities, national veterinary services and international veterinary information
organisations such as the IUCN/SSC Veterinary Specialist Group or the OIE Working
Group on Wildlife Diseases and for zoonoses, the Institut Pasteur in Paris (and in other
countries), and the World Health Organisation in Geneva, may be consulted. (See
appendix for organisation addresses).
Consultation with veterinarians in the source area should be sought to determine if any
diseases of concern are known to be enzootic in domestic livestock or wildlife in the source
area. In some cases it may be desirable and possible to sample the wild animal populations
in the source and destination areas by serology and autopsy. Positive serologic results may
warrant further investigations to detect the presence of active infections. Opportunistic
sampling of hunter-harvested animals, road kills and rehabilitation centre casualties may
also be undertaken.
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The quarantine protocol, the list of screening procedures and the treatment/vaccination
suggestions which follow are as comprehensive for each taxon as possible and represent
those procedures that should ideally be performed when adequate funding, laboratory
services and veterinary expertise are available. It is well recognised that this may not always
be the case and in these circumstances close liaison between the conservation authorities
and their veterinary advisors must be maintained so that the health hazards, which are
implicit in all wild animal translocations, can be objectively assessed and where possible,
minimised. It may well be that the veterinary risks which are judged to accompany a given
translocation proposal are so great that in no circumstances should that operation be
permitted to proceed.
In some cases it may not be possible to adhere to these guidelines because the health and
welfare of the species to be released will be jeopardised if the animal is held in close
confinement for a long period. For example, some species of New Zealand’s small birds
(robins) will die if confined for as little as 24 hours. In these cases, the risks of translocation
must be judged against the benefits of releasing the animals.

Quarantine

7, 8, 15

The purpose of quarantine is to allow the detection of those animals, which may be
incubating a disease with a short incubation period and also to detect the clinical signs of
diseases with a longer incubation period.
When captive wild animals are to be returned to the wild, for whatever reason, they should
be isolated from all other animals not of the same consignment, in suitable secure premises,
approved by a veterinarian, for at least 30 days immediately before shipment for release.
For many species pre-shipment quarantine may be an international requirement, especially
if the origin of the animals is another country. The recipient country may also have
regulations regarding post-shipment quarantine.
Quarantine premises must be appropriate for the species concerned and must take into
account the epidemiological situation in the region or country of origin and that in the
destination area. Thus, very finely netted enclosures may need to be provided where the
vectors of vector-borne diseases (e.g. African horse sickness and bluetongue) must be
excluded. The premises must allow adequate visual access and permit clinical examination,
sampling and when necessary, chemical rather than physical restraint. Isolation from all
possible sources of infection must be absolute.
The main requirement is that a group of wild animals (or a single animal) under quarantine
must be isolated from all others of its own or closely related species and if possible, from all
other species, wild and domestic, too. In the case of primates this will mean isolation from all
humans other than the attendants.
Quarantine for all species should be for a minimum of 30 days and should be under the
supervision of a veterinarian. The 30 day minimum quarantine period may need to be
extended in the case of diseases which exhibit a long and often unpredictable incubation
16
period (e.g. rabies, tuberculosis) and in other special circumstances.
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For cervids in USA, guidelines for quarantine are linked to testing requirements for
brucellosis and bovine tuberculosis. Fulfillment of these guidelines requires that animals with
no prior testing history be held in their State of origin, in isolation, for at least 93 days. This
minimum period allows for the required 90 days interval between two consecutive tuberculin
tests and an additional three days for reading the second test.
Test requirements for brucellosis, which comprise a negative test within 30 days prior to
shipment can be satisfied within this time frame.
Quarantine should always be conducted on an "All in, All out" basis. Should an animal
undergoing quarantine in a group with others of the same species contract an infectious
disease or test positive for an infectious disease while in quarantine, it must be removed
from the group and placed in isolation. The whole group must then undergo a further 30 day,
or longer, period of quarantine with appropriate testing. The length of the quarantine period
will depend again on the incubation period of the disease concerned.
The attendant of specific groups of wild animals under quarantine must care for them alone
and should not visit or come into contact with animals of similar taxonomic groups which
may be undergoing quarantine in an adjacent domestic animal quarantine station. The
attendant should also refrain from contact with all domestic animals, other exotic animals or
contaminated foodstuffs, for the period of the quarantine.
Equipment used to feed and water the quarantined wild animals and to clean their
enclosures must be used for these animals alone. Such equipment must be regularly
disinfected with an appropriate disinfectant, designated by the attending veterinarian.
All dung-soiled bedding and discarded foodstuffs must be disposed of in a hygienic manner,
preferably by burning.
Precautions must be taken to minimise the risk of exposure of the quarantine staff to
zoonotic diseases that may be present in the newly acquired animals. These precautions
should include the use of disinfectant foot baths, wearing of appropriate protective clothing,
masks and gloves and minimising physical exposure to some species, e.g. primates by the
wearing of face masks and by the use of chemical rather than physical restraint.
Appropriate vaccination of the quarantine staff should be carried out.
During the quarantine period all animals, especially longhaired or woolly species, should be
carefully checked to ensure that they are not inadvertent carriers of the seeds of plants
exotic to the release area. Similarly they should be checked for infestation with ticks, which
may be the vectors of diseases exotic to the release area.
Clinical examination and diagnostic testing
Unfortunately, most existing diagnostic serological tests have been developed for use in
domestic livestock species and their validity for wildlife has not been ascertained.
Furthermore, some assays require species-specific reagents, which probably are not yet
commercially available. Many such assays have not yet been standardised. Consequently
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great care must be taken when using these tests to determine whether an animal or
9
population is infected and in making decisions regarding proposed translocation.
A licensed veterinarian who has experience of the species concerned and of the likely
diseases to which they may be susceptible, should carry out a thorough inspection of the
animals destined for translocation.
At the first opportunity, each animal must be tagged, tattooed, or transpondered and in the
case of primates, photographed, for permanent identification.
The inspector will note all visible conditions, including abnormal gait and behaviour,
anorexia, diarrhoea, emaciation, salivation, polydipsia, hair loss and traumatic injuries.
It will be seen that some of the tests (checks) that should be carried out on animals while
they are in quarantine prior to release are relatively simple and require little in the way of
equipment. However, others will require access to a sophisticated laboratory, staffed by
personnel experienced in the diagnosis of wildlife diseases. Interpretation of the results of
the tests should be made by an experienced veterinarian who is familiar with the taxon
concerned and the epidemiological situation in the areas of origin and destination.
On the basis of the results of the clinical examination and the laboratory tests, the
veterinarian, in consultation and agreement with the relevant conservation authorities, shall
decide whether the animal(s) shall be:
1.

Translocated and Released

2.

Definitely not Translocated or Released. (Maintenance in captivity or euthanasia may
have to be considered)

3.

Considered for Translocation and Release only after further investigation, quarantine
and/or treatment.

Decisions on whether to add or omit a test, a treatment or a vaccination procedure must be
left to the veterinarian overseeing the quarantine and the Translocation/Release.
In cases where a zoonosis may be translocated by a `carrier' animal, it may be advisable to
consult the Centre for Disease Control (CDC) in Atlanta, USA and/or the World Health
Organisation (WHO) in Geneva, Switzerland and/or the Institut Pasteur in Paris, France.
Since animals are sometimes captive-bred on one continent for eventual release into the
wild on another, international export and import regulations governing disease control may
apply. These may dictate a pre- as well as a post-export protocol. Such animals are termed
`imported' in this booklet.
Finally, we must reiterate that it must always be remembered that once a wild animal
has been released into the wild, it is very rarely possible to recover it or the potential
pathogens it may have carried.
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Restrictions on origin and destination
Examples of such restrictions are:
Artiodactyla should not be translocated to or from geographic areas or populations which are
known to harbour wild or domestic ungulates infected with chronic wasting disease
(Cervidae in USA), brucellosis, bovine tuberculosis, paratuberculosis, foot and mouth
disease, rinderpest or septicaemic pasteurellosis.
White-tailed deer (Odocoileus virginianus) in USA carry a parasitic nematode
(Parelaphostrongylus tenuis) in their meninges. This parasite, the intermediate host for
which is a small land snail, is well tolerated by the deer. However, moose (Alces alces), are
very susceptible, as are caribou (Rangifer tarandus) and most other cervids. Thus whitetailed deer should not be translocated into areas occupied by moose, caribou or other large
Cervidae for which the meningeal worm can cause fatal disease. Conversely, moose,
caribou and some other susceptible cervids would be unlikely to thrive in areas already
occupied by white-tailed deer that are carrying P. tenuis.
Carnivores originating in rabies or Echinococcus sp. enzootic areas should not be released
in rabies or Echinococcus sp.-free areas. Birds from Newcastle disease infected areas
should not be released in Newcastle disease-free areas.
Due to the high sensitivity of otters (Lutra lutra) to polychlorinated biphenyls (PCBs), these
animals should not be released into areas where the food web and environment is
contaminated with these compounds.
Regulations of the Convention on International Trade in Endangered Species of Wild Fauna
and Flora (CITES) may apply and if so, should be strictly complied with.

Pre-release treatment
During the quarantine period, certain prophylactic measures may be instituted. Individual
faecal samples or representative samples from large numbers of individuals housed in a
limited area (e.g. birds of the same species in an aviary or frogs in a terrarium) should be
collected at least twice and examined for endoparasites. Treatment, if not contra-indicated,
should be prescribed by the attending veterinarian.
Animals should be free from therapeutic drugs for a minimum of one week prior to release
into the wild. This precaution will prevent the drugs masking the signs of disease and will
minimise the risk of the development of drug resistant organisms in the release
environment.

Endo- and Ecto-parasites
Ideally, endoparasitic burdens should be evaluated on at least two occasions, three weeks
apart, during quarantine. It may not be deemed necessary to administer anthelmintics if the
revealed parasite load is light and if the species found are those likely to be encountered by
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the released animals at their destination. However, heavy parasite burdens, which are often
acquired in captivity, should be controlled before the animals are released and it may be
desirable to eliminate a specific parasite if this is known not to occur in the proposed release
environment. In addition, all animals should be evaluated for ectoparasites (especially
sarcoptic mange, screw worm, warble fly and tick infestation) and treated accordingly.
When controlling endo- or ecto-parasites it is important to be clear what the objective is. In
some circumstances, when the aim is to prevent the introduction of exotic, non-indigenous
species, an attempt at complete elimination should be made. In another situation, the aim
might be to reduce the parasite burden in order to minimise stress on the host. If the
objective is complete elimination, (which may be difficult), then repeated follow-up checks
may be required to ensure that this has been achieved and the animals should not be
cleared for release until after the pre-patent period for the parasite in question has elapsed
Some parasitic worms (eg. Echinococcus sp.) will die out during the quarantine if the period
is long enough (> two months) and reinfection is prevented.

Vaccination/Immunisation

15

The question of the desirability of pre-release vaccination should be carefully considered
and the decision whether or not to immunise the animals to be released should be made by
the attending veterinarian, after evaluating the immunological status of the animals held in
quarantine and the likely challenge by enzootic and exotic disease agents upon release.
Vaccination of wild ungulates against enzootic diseases of contiguous domestic livestock,
such as rinderpest or foot and mouth disease, may be indicated, as may vaccination against
diseases known to be present in the release environment, such as clostridial diseases and
anthrax.
It might be argued that immunisation of translocated animals against enzootic local diseases
in the environment is contra-indicated because they would thus be afforded an unfair
selective advantage over the resident wildlife. But this is not necessarily the case, because
the resident wildlife would probably have been challenged under natural conditions when
young, while under partial protection via colostral immunity, and would presumably have
acquired a solid immunity later. In addition, usually only the founder generation of
translocated animals would receive vaccine protection.
It is important to remember that some of the potential pathogens (e.g. Bacillus anthracis and
Clostridium botulinum), which may occur in a release area are as much a part of the
environmental biodiversity as are the animals to be released and have exerted selective
pressures on unvaccinated wildlife for a very long time. These pressures have enabled the
survivors to adapt to their environment and to resist the pathogenic challenge. One can thus
probably afford to ignore these enzootic diseases, provided that the original foundation stock
is vaccinated before release, so as to give it the greatest chance of survival while its
numbers build up to the levels needed to preserve genetic fitness. Follow-up vaccination for
subsequent generations would in any case be expensive, difficult to carry out and probably
only justified for highly endangered species.

14
It is recognised that the advice given to repeat many of the vaccination procedures ‘at
suitable intervals' may not be possible when animals are held in quarantine for only 30 days.
But animals bred in captivity for eventual release into the wild can usually be subjected to
the recommended vaccination protocol. Animals born and raised in the wild may already be
resistant to the enzootic pathogens and thus may not need vaccination. This is another
reason to check relevant titres as part of the screening process and to evaluate each
individual case.
When vaccination is considered, it is important to remember that modified live vaccines,
especially those against viral diseases designed for use in domestic animals, may be
extremely dangerous when applied to wild animals. Not only may they cause fatal disease
but the vaccinated animals may shed live virus into the environment, which could then infect
free-living populations. Furthermore, the efficacy of most vaccines manufactured for
domestic livestock is completely unknown when they are applied to wild species. Some
vaccines, licensed to protect a domestic animal after a single dose (e.g. killed rabies
vaccine), may fail to provoke a strong and sustained antibody response when applied to wild
10, 11, 14
species and may need to be repeated on a number of occasions.
It is recommended that where possible, animals should be vaccinated several weeks prior to
the planned release in order that adverse reactions, such as vaccine-induced disease or
immunosuppression (especially if live vaccine has been used), may be detected.
If there is any doubt as to the safety of a particular vaccine for wildlife and there is a choice
between a live vaccine and a killed (inactivated) vaccine, the killed vaccine should always be
used. In all cases, it would be wise to consult the vaccine manufacturers, local zoological
facilities and also related organisations, such as the American Association of Zoo
Veterinarians (AAZV), the American Association of Wildlife Veterinarians (AAWV), the
appropriate International chapter of the Wildlife Disease Association (WDA), the
Zoological Society of London (ZSL), the World Association of Wildlife Veterinarians
(WAWV), the European Association of Zoo and Wildlife Veterinarians (EAZWV), the
relevant reference laboratory (named by OIE or WHO) or the regional wildlife disease
authority, for specific advice.
The protection of free-ranging wildlife from the enzootic and epizootic diseases of
contiguous domestic livestock is best achieved by ensuring that the livestock is
regularly vaccinated against these diseases.
Other procedures
Accurate identification of the species and subspecies, and if possible, population of origin,
should always be made for all animals destined for translocation and release.
Whenever possible, whole blood, and blood in EDTA should be collected and the serum or
plasma banked. Either liquid nitrogen, a -70 degrees Celsius ultra freezer or a -20 degrees
Celsius freezer that is not self-defrosting, should be used to conserve sera. Such sera can
provide an important resource for retrospective disease evaluation.
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Whole blood for serum and blood in EDTA should be stored at +4 degrees Celsius, if
collected for a Complete Blood Count (CBC), and processed within 24 hours. Blood smears
are best made and air-dried as soon as possible after collection.
The quarantine period also presents an opportunity to identify permanently all unmarked
animals when they are anaesthetised or chemically restrained (e.g. tattoo, ear notch, ear
tag, microchip). In addition, whenever animals are restrained or immobilised, a complete
physical examination, including measurement of body weight and dental examination,
should be performed. Diagnostic specimens should also be collected and stored as above,
at this time.

Veterinary medical records
Complete medical records should be kept and be available for all animals during the
quarantine period. Animals that die during the quarantine period should have a necropsy
performed under the supervision of a veterinarian and representative tissues submitted for
histopathological examination, with other laboratory analyses (i.e. cultures) applied as
indicated.
The results of all tests, both positive and negative, should be recorded. Thus a bank of
baseline data will be developed.
Finally, the medical history and records of the human attendants, including the veterinarian,
must be kept and the attendants must be regularly screened for infection with transmissible
diseases (e.g. tuberculosis, chicken pox, mumps, influenza, hepatitis A and B) and be up to
17
date with rabies vaccinations and tetanus toxoid.

Ethical considerations

12, 13

.

The quarantine, screening, transport and release of captive-bred or wild-caught animals is
likely to cause a degree of stress, which could be significant in some cases. While
translocation or re-introduction schemes can have potential benefits for the viability of wild
populations, they may not be in the best interests of the welfare of the individuals involved.
It is therefore important that :

1. the balance of the welfare costs and conservation benefits should be kept under review
during translocation and re-introduction programmes,
2. no more animals are used than are judged to be necessary for the success of the
scheme, and
3. procedures (transport, handling, quarantine, release etc) are designed as far as possible
to minimise any harm or distress to the animals concerned.
Suitability for release. If the animal has been in a captive situation for a long time or if it
is captive born and raised, a careful assessment of the animal’s level of habituation, the
presence of aversion and flight behaviours, and its ability to compete for food and space
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in the wild should be made. It may not be advisable to release the animal if it appears to
be irreversibly habituated to human beings. In order to minimise this problem, all handling
for tourism purposes etc should be stopped at least 6 months prior to release.

The following are recommendations and suggestions for appropriate quarantine, health
screening, treatment and vaccination procedures for the major animal groups likely to be the
subjects of translocation and release into the wild. Whenever possible, national and
international reference laboratories experienced with the species or with closely related taxa
and the diseases concerned, should be consulted.

Treatment disclaimer
Many of the drugs and vaccines mentioned in this booklet are not registered for use
in wild animals. It is possible that they may produce unexpected and undesirable
reactions, even death.
It is therefore recommended that the veterinarian in charge of any health screening
project for wild animals, prior to their release into the wild, should obtain and
administer all drugs in accordance with the relevant national Veterinary and Poisons
legislation.
The mention of specific drugs and vaccines and their manufacturers, by name, does
not imply a recommendation by the publisher, editor or sponsors. This information is
given merely to indicate what products are available and to suggest their source.
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The following worksheet provides a suggested Checklist for Quarantine and Health
Screening of wild animals prior to Translocation. Please read the Explanatory Notes at the
end of the Worksheet before completing the form.
__________________________________________________________________________

Quarantine and Health Screening Worksheet for Animal Movements
__________________________________________________________________________

1.

SPECIES TO BE MOVED:………………………...………………………...

2a.

FROM:…………………………… 2b. TO:…………..……………………..

3.

NUMBER OF ANIMALS:…………………………………………………….

4. ANIMAL ID
ID Number

ID TYPE

AGE

SEX

OUTCOME

COMMENTS

Attach additional sheet if needed.
4.

ANIMAL MOVEMENT CATEGORY:

Wild to wild
Wild to captivity
Captivity to wild
Captivity to captivity

6a.
6b.

PROJECT MANAGER:…………………………………… Tel:……………
TITLE, INSTITUTION:…………………………………… Email:………...

7.

PROJECT VETERINARIAN:………………………….… Tel:……………
Email:…………
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8.

DISEASES OF CONCERN (relevant to source animals and destination animals including
wildlife, domestic animals and humans). If more space needed, attach additional sheet to
this form and include references

9. SPECIFIC DIAGNOSTIC TESTS
(for documentation refer to individual animal records):

10. ROUTINE SCREENING/DIAGNOSTIC SAMPLES
(for results refer to individual animal records)
Diagnostic samples to be collected (check)
Physical exam, body weight and measurements
faeces
Blood smear, haematocrit and total protein
Whole blood, serum or plasma (max. volume / animal =
)
Fresh faecal or rectal swab for culture
Choanal or oral swab for culture
Ectoparasites
Other:

11. TREATMENTS/VACCINATIONS AND DATES
(for documentation refer to individual animal records):

Collection
dates

Date results
received
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12. SAMPLES TO BE FORWARDED TO:
………………………………………………………………………………………
………………………………………………………………………………………
……………………………………………………………………………………….
………………………………………………………………………………………

Quarantine Details
13.

LOCATION:…………………………………………………………………..

14.

FACILITY:…………………………………………………………………….

15. QUARANTINE DURATION: Begins……………… Ends……………………
Date
Date
Total Days:………………….
(If less than 30 days specify reason: ………………………………………………..
……………………………………………………………………………………….)
16. PERSON SUPERVISING QUARANTINE: ………………………………….....
Tel:………………………………… Email:…………………………………...
17a.

TRAINING NEEDED FOR SUPERVISOR?

Yes

No

17b. DATE OF TRAINING, IF NEEDED:………………………………..
18. QUARANTINE EQUIPMENT:
“Quarantine – no
unauthorized entry” sign
Insect/rodent traps/
screens/baits
Diagnostic sample
collection, storage and
transport equipment
Lock for facility
Footbath/boot changes

Protective clothing
Cage furniture as
appropriate for the species
Animal record forms, pens

Bags for waste disposal
Other:

Feeding, watering and
cleaning utensils
Animal capture /
restraint equipment
Quarantine register

Animal caregiver health
check
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19.

BUDGET:
Personnel hours _________@_________
Equipment costs
Feed costs
Lab costs
Courier fees
Veterinary fees
Other (specify)

_____________
_____________
_____________
_____________
_____________
_____________
_____________

TOTAL COST

_____________

Budget Code _________________________________________

Movement Recommendation
20a. Healthy and minimal threat to destination populations

OK to move

20b. Healthy but there is a significant threat to source animals

Delay move
Cancel move

20c. Unhealthy or threat to destination populations

Delay move
Cancel move

Explanation and justification for recommendation:
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21.

FOLLOW UP ACTIONS:

22.

PERMITS TO MOVE ANIMALS:

YES

NO

23. SIGNED OFF BY:_____________________________ DATE ______________
Project Manager
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Quarantine and Health Screening Worksheet Explanatory Notes
1.

Species to be moved: A separate sheet should be used for each species of animal moved.

2a.
2b.

From: Point of origin of animals to be moved.
To: Location to which animals will be moved.

3.

Number of animals: Total number of animals to be moved

4.

Animal ID: Each animal should be individually identified or a colony number assigned
where individual identification is not possible. (e.g. amphibians or schools of fish):
Identification Number = number found on tag, tattoo, microchip, etc
ID type = tag, tattoo, etc.
Age = in years or where unknown classify as juvenile or adult
Sex = male, female, unknown
Outcome = Final disposition of each individual (e.g. moved, move delayed, canceled)
Comments = explanation of outcome
(Note “Outcome” and “Comments” in this table are inserted at the completion of the animal
movement)

5.

Animal movement category: Check the appropriate box

6a.
6b.

Project manager: person responsible for the animal movement.
Title, Institution: Project manager’s position in organization and name of organization

7.

Project veterinarian: Designated veterinary advisor for this project.

8.

Diseases of Concern: A complete list of diseases to which the species and its close relatives
are susceptible should be compiled and evaluated for consideration of impact upon the
animal movement. From this list those diseases which are likely to have a significant impact
on source and/or destination populations are identified as “diseases of concern” for this
animal movement.

9.

Specific Diagnostic Tests: All specific diagnostic tests to be performed during quarantine,
based upon diseases of concern (see number 8.)

10.

Routine Screening/Diagnostic Samples: With assistance from the project’s veterinary
advisor check the diagnostic samples to be collected and plan the date of collection. (Note
that a physical exam should be performed on every individual animal). Additional
diagnostic samples may need to be collected according to the needs of each diagnostic test.

11.

Treatments/vaccinations and dates: List all planned treatments and vaccinations to be
given during the quarantine period.
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12.

Samples to be forwarded to: List each laboratory’s address and phone number. Make
arrangements with laboratory prior to sampling. For some samples special handling and
laboratories may be needed.

Quarantine Details
13.

Location: geographic location of quarantine (e.g. zoo, park, island, )

14.

Facility: specific building or site of quarantine.

15.

Quarantine duration:

Begins = the date the quarantine begins
Ends = the last day of quarantine
Total Days = total number of days of quarantine

Explain the length of quarantine chosen if it is less or greater than the standard 30 days. Animal
husbandry issues (e.g. stress in captivity) may require that the quarantine period be shortened to
less than 30 days; the length of time for test results to be received or a particular disease with a
long incubation period may require that the quarantine period should be longer than 30 days.
16.

Person supervising Quarantine: Name the individual responsible for maintaining animal
health and quarantine status. Include his/her contact details.

17.

a. Training needed for supervisor?: Indicate if the supervisor needs training in quarantine
procedures and responsibilities (This may simply be a briefing).
b. Date of training, If needed: schedule date for training/briefing.
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18.

Quarantine Equipment: Check the appropriate boxes when the items listed have been
organized.

19.

Budget: identify costs associated with this animal movement project and include the
appropriate budget codes(s).

Movement Recommendation
20.

a, b or c: Check the appropriate box.
Use the accompanying box to explain and justify the decision made. Final recommendations
to be based on results of health screen and disease considerations as listed in number 8.

21.

Follow up actions: Indicate here any actions needed to follow through this animal
movement. e.g., post movement surveillance of .animals, review of animal movement
procedures, etc.

22.

Permits to move animals: Check the appropriate box to indicate if necessary permits to
move the animals have been received.

24
23.

Signed off by: At the completion of the animal movement project the Worksheet should be
signed off and dated by the project manager.

21.

This draft Quarantine and Health Screening Worksheet for Animal Movements has been
written by Dr. Richard Jakob-Hoff, BVMS, Auckland Zoological Park, Grey Lynn,
Auckland, New Zealand, and is reproduced here by kind permission of the New Zealand
Department of Conservation.
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Summary

Plan the Health Screen

Movement Category

Wild

Captive

Wild

Captive

•
•
•
•

Diseases of concern
Routine screening
Diagnostic tests
Treatments/vaccinations

Plan Quarantine Details
•
•
•
•
•
•
•
•

Location
Facilities
Equipment
Budget
People
Responsibilities
Training
Records

Quarantine Duration
Based on:Animal husbandry
Diagnostic testing
Disease criteria

Risk Decision

Review Outcomes
Healthy

Unhealthy

Carriers

Follow-up Actions

•

Healthy and minimal threat
to destination population

•

Healthy but threat to source
populations

•

Unhealthy or threat to
destination population

Movement Recommendations
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ARTIODACTYLA
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Certification
An appropriate Zoo-Sanitary Certificate, duly signed by an Official Veterinarian of the
exporting country, should accompany all imported animals destined for release into the wild.
This certificate will contain information concerning any tests or vaccinations, which have
been carried out prior to shipment. It may, however, be deemed advisable to repeat some or
all of these tests after arrival during the quarantine period.
Ruminants imported from Foot and Mouth Disease (FMD) enzootic areas, especially from
Africa, must be subjected to the "probang test" so as to exclude the presence of any FMD
virus. The "probang test" samples must be examined at an approved FMD Reference
Laboratory (Pirbright, UK or Onderstepoort, South Africa) and the results should be known
before the animals leave the country of origin. Strict regulations govern the import of animals
from FMD enzootic countries or areas, into FMD-free countries.
There are other potentially devastating diseases that also merit thorough attention as listed
1
below.

Health screening while in quarantine
The suggested screening procedures, which follow, are necessarily lengthy. However, they
may be modified and adapted depending on the genus and species of the translocated
animals, their source (a zoo? a ranch? the wild?), their country or area of origin and
destination, their period in captivity and their disease history. Interpretation of the results of
the tests must also take the above information into account, along with knowledge of the
epidemiological situation for the various diseases in the countries of origin and destination.
Tests, which give negative results (especially faecal examinations for endoparasites), may
be repeated several times at suitable intervals. Where testing for exotic diseases is not
possible locally, samples may have to be sent to an approved laboratory in another country.
However, note that the shipment of diagnostic specimens may require various permits
(including those from CITES) from the authorities in both the country of export and the
country of import.
Quarantine for artiodactyla should be for a minimum of 30 days (see page ? for special
quarantine period to allow for requirements for testing for tuberculosis and brucellosis)
during which the following procedures should be carried out:
1.

Faecal examination (direct, flotation and sedimentation) for endoparasites, (especially
Fasciola magna, which is best screened for by sedimentation procedures).

2.

Baermann tests for lungworm larvae.

3.

Faecal culture for Johne's disease and Salmonella sp.
(For Salmonella sp. culture it is recommended that multiple samples be taken over
time and for Johne's disease it should be noted that conventional culture could take
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12-18 weeks). However, radiometric mycobacterial culture techniques are much
faster and can be completed in 6–8 weeks.
Note: ELISA and AGID (Agar Gel Immuno-diffusion test) are not validated for use in
non-domestic hoofstock and in many instances have not produced satisfactory
results. See “Proceedings of the Workshop on Diagnosis, Prevention, and Control of
Johne’s Disease in Non-Domestic Livestock”, White Oak Conservation Center, 3823
Owens Road, Yulee, Florida 32097, U.S.A. July 26-28, 1998, pp. 63.
4.

Examine blood smears for haemo-parasites. Carry out serology and if appropriate,
xenodiagnosis, for important haemoparasites for those animals, which are negative
on blood smear examination.

5.

Complete Blood Count and Packed Cell Volume (PCV).

6.

Examine the buffy coat of micro-haematocrit tube blood samples for trypanosomes
and/or microfilariae.

7.

Urinalysis when possible.

8.

Serum/plasma chemistry profile (this may be expensive and unnecessary).

9.

Serology for brucellosis (multiple tests are desirable for all exotic artiodactyla).

10.

Serology or PCR for malignant catarrhal fever (MCF), bovine virus diarrhoea (BVD),
rinderpest (RP), peste des petits ruminants (PPR), lumpy skin disease (LSD),
bluetongue (BT), epizootic haemorrhagic disease (EHD), Infectious bovine
4
rhinotracheitis (IBR), leptospirosis, anaplasmosis.

11.

Virus isolation tests for bluetongue and epizootic haemorrhagic disease - these tests
must be carried out during the pre-export quarantine (where applicable) and any
animals found to be viraemic with BT must be rejected. Virus isolation tests for EHD
are needed only for animals originating in USA. Note: Since ungulates that recover
from rinderpest never re-excrete the virus, those that test serologically positive for
rinderpest antibodies may be judged to be virus-free and safe to translocate after 30
days in quarantine.

12.

Serological tests for tuberculosis (ELISA, Gamma-interferon etc.). Intradermal skin
tests may be useful but must be carefully interpreted (e.g. false positives in caprines).

3

5

Advice on appropriate tests for tuberculosis in various species may be obtained from:
Central Veterinary Laboratory, Lelystaad, Holland; Central Veterinary Laboratory,
Weybridge, Surrey, UK; Ministry of Agriculture Veterinary Laboratory, Invermay,
New Zealand; Onderstepoort Veterinary Institute, Pretoria, South Africa;
USDA/APHIS, AZA Animal Health Committee and CNEVA, France.
See also “Tuberculosis Surveillance Plan for Non-Domestic Hoofstock” currently
being developed by the National Tuberculosis Working Group for Zoo and Wildlife
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Diseases, chairperson: Dr. S. Mikota, ACRES Species Survival Center, 140001 River
Road, New Orleans, Louisiana 70131, USA.
13.

Check for mycoplasmal kerato-conjunctivitis (especially in chamois (Rupicapra sp.)
mouflon (Ovis musimon) and ibex (Capra ibex)). Some animals may be symptomless
carriers and this infection can recur up to three months after recovery from clinical
disease. Recovered animals should not therefore be moved into areas free from this
9
disease.

14.

Check for ectoparasites (especially sarcoptic and psoroptic mange, warble fly larvae,
nasal bot fly larvae, screwworms and ticks).

15.

Ear mark, tag or insert microchip when possible.

16.

Ultra-freeze suitably labelled serum and tissue samples.

Pre-release immunisations
As appropriate, any or all of the following immunisations may be made after taking into
consideration the epidemiological situation in the country or region of origin and the eventual
destination of the animals. In most cases a killed, inactivated vaccine is preferable to a
living, attenuated product. While rinderpest vaccine will protect against PPR and vice versa,
in most cases it is better to use PPR vaccine for small ruminants, so as to avoid confusion
when later sero- sampling is carried out, especially in a country with RP-free status.
Anthrax (Bacillus anthracis). [Anthrax vaccine (Colorado Serum Company)].
Pasteurellosis (Pasteurella multocida, Types B & E)
Clostridial diseases (Clostridium chauvei, Cl. septicum and Clostridium
botulinum (Types C & D). [Vision 7, (Bayer Corporation) or Heptavac (Hoechst
Rousel Vet Ltd.)]
Rinderpest
Peste des petits ruminants
Foot and Mouth Disease (Types A, O, C, & Asia 1)
Rabies [Imrab 3, (Merial Ltd.)]
Infectious bovine rhino-tracheitis (Many vaccines are available, always use a
killed product such as Triangle 3, combined IBR, BVD, and PI3 (Fort Dodge
Animal Health)]
Bluetongue /Epizootic haemorrhagic disease
Bovine virus diarrhoea (BVD). [See above]
Contagious caprine pleuropneumonia (CCPP), (caprines only)
East Coast Fever (ECF), (+ prophylactic antibiotic)
Parainfluenza 3. [See above]
Leptospira 5-way bacterin (Many vaccines are available, such as Leptoferm-5,
(Pfizer Animal Health)]
Paratuberculosis (Johne’s Disease).Vaccine is now made in Spain for sheep
Note: Pre-release exposure to the vectors of protozoal haemoparasites may be
advantageous, if carefully controlled. For example, if a pre-release enclosure is
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located in low density tsetse fly (Glossina sp.) country, a low exposure to
trypanosomiasis will occur and a useful immunity may result. However, if the animals
are released without pre-exposure, they may choose a habitat with high tsetse fly
challenge with subsequent disease risk.

South American camelidae should be routinely immunised with tetanus toxoid (most
licensed products are satisfactory) and with a multi-valent clostridial toxoid such as Vision 7
with SPUR (Bayer Corporation) or Heptavac (Hoechst Rousel Vet Ltd.). However, there are
many other satisfactory multivalent clostridial vaccines available on the market. Low
volume, low reactivity products should be chosen because many clostridial vaccines often
cause local reactions and abscesses.
6

Llamas are very sensitive to some anthrax vaccine strains.

Other artiodactyla may be immunised against clostridial diseases according to local
6, 7, 8
exposure risk and history.
Suidae/Tyassuidae may be immunised against leptospirosis with a multi-valent bacterin
and against swine erysipelas. The need for these and other immunisations (e.g. Classical
swine fever) should be based on local history and risk of exposure.
Note: In any situation where immunisation of wild artiodactyla is being considered, the local
domestic animal disease regulatory authorities should be consulted. The effect of
vaccine on the subsequent ability to detect disease by serology must also be
considered. If a vaccinal titre cannot be distinguished from an exposure titre, the ability
to monitor disease in the wild after release may be compromised, eg. rinderpest.

Pre-release treatment
1.

All ruminants should receive two treatments, 14 days apart, with a recognised
flukicide to control fascioliasis. In the USA, Albendazole, Valbazen (SmithKline
Beecham Animal Health) or Clorsulon, Curatrem (Merck Agvet) can be used. In
other countries these products may be available under different names.

2.

All ruminants should be treated with an anthelmintic in the avermectin group (i.e.,
ivermectin (Ivomec, Merck Agvet), doramectin (Dectomax, Pfizer Animal Health),
eprinmectin (Eprinex, Merial Ltd.), or moxidectin (Cydectin, Fort Dodge Animal
Health)) at appropriate dosage during pre-import quarantine and again during postimport quarantine. Such treatment will control or eliminate endo-parasites and ectoparasites (especially warble fly larvae and nasal bot fly larvae). Doramectin and
Moxidectin have much longer lasting effect times than Ivermectin in ruminants.

Note: If mature warble fly larvae are manually squeezed out of the skin, great care must be
taken to ensure that the larvae are not crushed, as this may precipitate a serious
anaphylactic reaction. Avermectins, administered when the warble-fly larvae are
approaching maturity under the skin, can cause a similar reaction).
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3.

Where necessary, administer trypanocidal treatment for trypanosomiasis.

4.

Administer appropriate treatment for rickettsial diseases, if necessary.
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PERISSODACTYLA
These recommendations are based on those for domestic equidae (except where noted
otherwise) which have been imported from another country. As appropriate, they can be
adapted to cover wild equids, tapirs and rhinoceroses, which are destined for release into
the wild.
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Certification
An appropriate Zoo Sanitary Certificate, duly signed by an Official Veterinarian of the
exporting country, should accompany all imported animals destined for release into the wild.
This certificate will contain information concerning any tests or vaccinations, which have
been carried out prior to shipment. It may be deemed advisable to repeat some or all of
these tests after arrival, during the quarantine period.

Health screening while in quarantine
The suggested screening procedures that follow are necessarily lengthy. However, they may
be modified and adapted depending on the genus and species of the translocated animals,
their source (a zoo? a ranch? the wild?), their country of origin and destination, their period
in captivity and their disease history. Interpretation of the results of the tests must also take
the above information into account along with knowledge of the epidemiological situation for
1
the various diseases in the areas or countries of origin and destination.
Where testing for exotic diseases is not possible locally, the samples may have to be sent to
an approved laboratory in another country.
Quarantine for equids should be for a minimum of 30 days during which the following
procedures should be carried out:
1.

Faecal examination (direct and flotation) for endoparasites.

2.

Baermann tests for lungworm larvae (especially wild asses).

3.

Submit a serum sample to an approved Reference Laboratory for testing for African
horse sickness. (This should have been done during pre-export quarantine in the
country of origin and any animals testing positive should not have been shipped).

4.

Submit serum samples from each animal to an approved laboratory for the following
tests:
a. Complement fixation test for dourine (Trypanosoma equiperdum).
b. Complement fixation test for glanders (Pseudomonas mallei).
c. Immunodiffusion (Coggins test) for equine infectious anaemia.
d. Serum neutralisation test for equine viral arteritis.
e. Test for equine herpes viruses (zebras and onagers)
f. Test for Potomac Horse Fever/Erlichiosis (Erlichia risticii), if from an enzootic area.
All the above tests must prove negative.

* Any animal which tests positive for any of the first four of the above diseases should
be retested and if still positive, should be destroyed at once!
5.

Examine blood smears for haemo-parasites (Babesia equi and B.caballi, Erlichia
risticii). Carry out serology on those that are negative on blood smear examination.
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6.

Examine the buffy coat of micro-haematocrit tube blood samples for trypanosomiasis
(Trypanosoma evansi). Examine those negative for trypanosomes by ELISA test.

7.

Test tapirs (Tapirus sp.) for bovine tuberculosis.

8.

Complete Blood Count and PCV.

9.

Serum/plasma chemistry profile.

10.

Urinalysis if possible.

11.

Check for ectoparasites.

12.

Check for endoparasites.

13.

Ear mark, tag or insert microchip when possible.

14.

Ultra-freeze suitably labelled serum and tissue samples.

Pre-release immunisations
As appropriate, all or some of the following immunisations should be made after taking into
consideration the local epidemiological situation and the eventual destination of the
2
animals :
Tetanus [Many vaccines are available–Super-Tet (Bayer Corporation)]
Rabies [Imrab 3 (Merial Ltd.)]
Anthrax [Anthrax Vaccine (Colorado Serum Company)],
Equine influenza [(Many vaccines are available – use a killed product such as
Fluvac or Duvaxyn IET-Plus, which also contains tetanus toxoid (Fort Dodge
Animal Health)]
Equine herpes virus type -1 (rhino-pneumonitis) [Many vaccines are available
–use a killed product, such as Prestige with Havlogen (Bayer Corporation)]
Encephalo-myelitis
Strangles
Botulism
Eastern equine encephalitis (EEE). Many vaccines are available –use a killed
product, such as Encephaloid (Fort Dodge Animal Health)]
Western equine encephalitis (WEE). [Encephaloid contains both EEE and
WEE antigens].

Black rhinoceroses (Diceros bicornis) should be immunised against leptospirosis with a
multivalent leptospirosis bacterin including L. interrogans var.icterohaemorrhagiae (after first
checking leptospiral titres). The Black Rhino American Zoo and Aquarium Association
(AZA) Species Survival Plan (SSP) recommends using Leptoferm-5 (Pfizer Animal Health).
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Vaccination should be carried out annually. The use of BratiVac-6 (Pfizer Animal Health) for
both black and white rhinos may be indicated because it has the L. bratislava
serotype.added.
Note: Vaccination of black rhinos in captivity against leptospirosis has had significant side
effects. These have ranged from sweating to severe sloughing of the skin. However,
vaccination is still recommended. Check for tick infestation (possible vectors of cowdriosisheartwater). If present, treat with an acaricide.

Pre-release treatment
1.

As appropriate, suitable anthelmintics can be administered to remove or control
endoparasites, especially liver flukes in tapirs.

2.

Appropriate pyrethrin-type or pyrethroid acaricides should be applied, [Permectrin 11
(Boehringer Ingelheim Animal Health) may be used but there are many others] and
any of the previously mentioned avermectins should be considered for the elimination
of ectoparasites.

3.

Appropriate treatment should be applied to eliminate any detected haemo-parasites.
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PRIMATES
The following are recommendations and suggestions for appropriate testing procedures for
diseases of primates held in quarantine.
If primates have been held captive and in close contact with humans, care must be taken to
screen them for all those diseases that are transmissible between human and non-human
primates. Information about such diseases on a regional basis can be obtained from local
medical authorities but it is important to remember that if foreign research workers or tourists
have had access to the primates, exotic infections acquired overseas may occur in both the
human and non-human primates.
The risk of zoonotic disease transmission, in both directions, is greatly reduced if all
attendant staff always wears facemasks, gloves and gowns when in contact with primates.
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Health screening while in quarantine
In view of the high risk of primates carrying zoonotic diseases, quarantine requirements are
stringent. Primates should be held in strict quarantine for at least 30 days after arrival and
before any further relocation. Many institutions insist on 60 days of quarantine and increase
this to 90 days for animals of unknown medical histories, those with known exposure to
1, 2, 13
infectious disease, or for wild-caught animals.
1.

Faecal examination (direct and flotation) for endoparasites, especially Entamoeba sp.
which often infect primates, causing diarrhoea in animals subjected to stress. Since
Entamoeba sp. are shed intermittently, several samples should be examined.
Primates should have three consecutive negative faecal examinations before
release. Faecal samples from New World primates should be examined by
sedimentation to increase the likelihood of detecting Prosthenorchis sp. ova that may
be shed intermittently in small numbers. Where possible, a centrifugation technique
should be substituted for the flotation procedure as this technique is more sensitive
and will detect ova present in smaller numbers than standard flotation. Check for
Spirurid nematodes (carried by cockroaches), especially in small South American
primates, such as marmosets and tamarins.

2.

Faecal culture for Salmonella sp., Shigella sp. (Gorillas (Gorilla sp.) are particularly
susceptible)), Campylobacter sp. and Yersinia sp.
The need to carry out these tests should be based upon the history of the animals
and their origin. Since these organisms are often shed intermittently by primates,
which may exhibit no clinical signs of infection, three consecutive faecal cultures may
be required.

3.

Appropriate serology, based on history and origin, for toxoplasma, retroviruses,
parainfluenza, measles, cytomegalovirus, Simian Immunodeficiency Virus (SIV) and
Hepatitis A, B, C (HAV, HBV, and HCV). All Hepatitis virus infections in primates are
diagnosed serologically. Chimpanzees (Pan sp.) are the only primate species, other
than humans, that are susceptible to infection with all known human hepatitis viruses,
but they rarely show any clinical signs.
Given that the prevalence of hepatitis virus infections among the general human
population is high, especially in areas where faecal contamination of food and water
supplies is frequent, it is not uncommon to find primates that have already been
11
exposed to these viruses by their human caretakers and local contacts.
Although there is little evidence that HBV infection has been transmitted from
primates to humans, in view of the potential health risk for contiguous human
communities, non-human primates serologically positive for HAV, HBV or HCV (or
indeed any other major zoonosis), should not be released into the wild.
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Since it appears that HBV infection can occur naturally, without any clinical signs, in
12
some chimpanzee populations, it may be justified to release HBV-positive
chimpanzees into wild populations, when these are already known to be infected by
10
this virus and are suitably isolated from human settlements.
Personnel working with non-human primates should consider vaccination for both
HAV and HBV.
All Old World primates, including the Great Apes (Gorilla sp., Pan sp. and Pongo
8
sp.), should be serologically tested for Herpesvirus simiae (Herpes B).

Note: That the quarantine period for Herpes B infection in Old World primates is 42 days.
Some Macaque species (Macaca sp.) may shed this virus intermittently and may be
seronegative, latent carriers of Herpes B virus. Due to the lethal potential of Herpes B
virus for other primates, including humans, precautions must be taken to prevent
exposure. Macaques from the Philippines should be tested for Ebola-Reston virus (a
strain of Ebola virus) infection.
4.

Carry out serum/plasma chemistry profile.

5.

Carry out urinalysis if possible.

6.

Carry out complete Blood Count and PCV.

7.

Blood smears should be examined for Filaria sp. and Plasmodium sp. (malarial
parasites). Filarial Infections, however, seem not to be pathogenic.

8.

Three negative tests for tuberculosis should be performed at two-week intervals using
a tuberculin containing at least 1500 units/0.1 ml (eg. Mammalian human isolate,
Coopers Animal Health, Kansas City, Kansas, USA) or “old mammalian tuberculin”
(Pasteur Institute, Paris, France). The tuberculin should be injected into the upper
eyelid.

Note: Orang-utans (Pongo pygmaeus) and chimpanzees (Pan troglodytes) frequently
exhibit false positive reactions to intradermal tuberculin testing and further diagnostic
3,
evaluation may be necessary to determine their true status. 5
9.

Carry out chest radiography.

10.

Check for ectoparasites.

11.

Apply indelible tattoo or microchip for identification. Full-face photographs are a good
way to identify apes. All are different and can be used for recognition of individual
apes, even in the field after release.

12.

Ultra-freeze suitably labelled serum and tissue samples.
At least 10 body hairs, with hair follicles attached, should be collected for later DNA
analysis. These can be stored in dry envelopes and may be valuable when it is
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desirable to check for genetic origin before release, in order to avoid “genetic
pollution” of a recipient wild primate population. Use plastic surgical gloves and heatsterilised forceps when collecting the hairs.

Pre-release immunisations
Primates, especially those likely to be exposed to humans when “habituated” for tourism,
4, 6
should be appropriately vaccinated.
1.

Hepatitis: Chimpanzees can be vaccinated against hepatitis but if they are, it will be
difficult to assess their serological status later. It is thus not advisable to use hepatitis
vaccine if the apes are likely to be in close contact with humans after release.

2.

Poliomyelitis: Oral vaccine should be administered to the Great Apes at three, six
and nine months and at two years of age for young and juvenile apes. Adults of
unknown history should receive oral polio vaccine three times at two months
intervals.

Note: The use of oral polio vaccine in primates is somewhat controversial as live virus is
shed in faeces when this is given. For this reason, parenteral polio vaccine (which is a killed
product) is a better choice.
3.

Mumps: Infection with this virus can cause orchitis and subsequent sterility.
Vaccination may be advisable if contact with humans is likely.

4.

Measles: Due to the high mortality that this virus can cause in some species (eg.
colobus (Colobus sp.), silver leaf monkeys (Presbytis sp.) and New World monkeys),
vaccination is recommended, particularly for those primates likely to come into
contact with humans. Newly wild-caught monkeys are especially at risk and should
be vaccinated. Juvenile, captive bred monkeys born to immunised females, may
have prolonged maternal antibody protection and should be vaccinated at six months
of age, with a booster at one-year-old. In the Great Apes, maternal immunity may
last until the infant is 15 months old. Vaccination can thus be delayed until after that
time. Human measles vaccine can be used but may cause transient
immunosuppression or vaccine induced measles if animals are stressed soon after
vaccination. It is therefore recommended that the stresses of tuberculin testing or
shipment should be avoided soon after vaccination.
Rabies: Primates, like all mammals, are susceptible to infection with rabies virus.
Vaccination in rabies-enzootic areas is recommended. A killed, inactivated vaccine,
as recommended for human use, can be used but is expensive. Imrab 3 (Merial Ltd.)
has also been used.

5.

6.

Tetanus: All primates are susceptible to tetanus and should be vaccinated before
release. Standard human tetanus toxoid is suitable. A combination human vaccine
containing diphtheria, pertussis (whooping cough) and tetanus (DPT) is sometimes
used but since non-human primates are not susceptible to diptheria or pertussis the
use of this combination product is unnecessary.
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Pre-release treatment
1.

Appropriate anthelmintics
endoparasites.

2.

Ectoparasites should be eliminated before release by applying pyrethrin-based
acaricides and by administering an avermectin. Sarcoptic mange will require two
consecutive treatments with an avermectin, followed by a negative skin scraping.
Ivermectin (the porcine form) should always be injected subcutaneously. Abscesses
and skin ulceration have been seen in chimpanzees after the use of the bovine form
of “Ivomec”.
2.

should

be

administered

to

eliminate

or

control

Young apes, forcibly taken from their parents, are very sensitive to emotional
stress and frequently die in captivity, particularly if they have been badly
treated by their captors. A delicate balance must be found between the
requirements of veterinary quarantine and the emotional needs of the
orphans, which need continuous care and sympathetic attention if they are to
survive.
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CARNIVORA
For marine carnivores, see under Marine Mammalia.
Health screening while in quarantine
Quarantine for carnivores should be for 30 days unless rabies is a problem in which case
quarantine may be increased to six months.
Note: Rabies incubation period is highly unpredictable and in some species
may greatly exceed six months.
1.

Faecal examination (direct, flotation, sedimentation and Baerman technique) for
endoparasites.

Note: Intestinal ascarids of the genus Baylisascaris may occur in procyonids, mustelids and
ursids in North America. These ascarids are rarely important to their definitive hosts
but after the eggs of the nematode are shed in the host's faeces, the resultant larvae
are neurotropic and viscerotropic in small mammals, birds and occasionally, humans.
Wildlife that are normal hosts for this parasite are asymptomatic carriers; other wild
species can become victims of larval invasion and the introduction of Baylisascaris
sp. into a new environment could adversely affect wild rodents, lagomorphs and birds
in which larval migration causes blindness, ataxia and paralysis. Faecal
contamination by Baylisascaris infected animals has caused mortality in domestic
poultry and two fatal human cases have been reported.
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Note: Wolves (Canis lupus), foxes (Vulpes sp., Alopex sp., Urocyon sp.), coyotes (Canis
latrans), jackals (Canis sp.), hyaenas (Crocuta crocuta and Hyaena sp.) and wild
felids, must be carefully examined for infection with the tapeworms of Echinococcus
sp. and even if the presence of these very small cestodes is not confirmed, all these
animals should be treated with intramuscularly injected praziquantil [Droncit, (HaverLockhart, USA) and Bayer in Europe)]. Praziquantil does not kill the eggs of
Echinococcus sp. and the faeces and hair of infected carnivores are heavily
contaminated, thus presenting a very serious hazard to the human attendants and to
the environment.
Rodents are the intermediate hosts for E. multilocularis and ungulates (wild and
domestic) for E. granulosus. However, since the survival of the adult cestodes within
the gut of the final host is relatively short (1-2 months), a period of quarantine, during
which the carnivores are fed on cyst-free food, should remove the worms. Both
species of Echinococcus are dangerous and potentially lethal zoonoses.
2.

Check for ectoparasites, especially sarcoptic mange.

3.

Serology for Felidae: Exposure to Feline immunodeficiency virus (FIV) should be
determined using Western blots, IFAs and ELISAs. Subpopulations of some species
of large felids exhibit a wide range of lentivirus prevalence, with some subpopulations showing no evidence of infection. There are different specificities and
sensitivities among lentivirus assays being applied to non-domestic felids, suggesting
that assay choice is important and that caution is warranted in comparing and
1
interpreting data.

6

To determine infection with feline leukemia virus (FeLV), an ELISA test for the
presence of antigen should be used. To test for exposure to FeLV, an ELISA to test
for the presence of antibody should be used.
Note: No non-domestic felid that is FeLV antigen positive should be released
into the wild as this virus does not appear to be enzootic in either wild or
captive felid populations.
To date, FeLV antigen positive non-domestic felids appear to have acquired the
infection from domestic or feral cats.
Other infectious diseases of Felids to check for include: feline viral rhinotracheitis,
calicivirus, panleucopaenia, coronavirus/ feline infectious peritonitis and
toxoplasmosis (a zoonosis). Remember that previous vaccination will influence
interpretation of the results.
For herpes virus, calicivirus and toxoplasmosis infections, a carrier state is probable.
The risk of release into the wild of carrier felids depends on the risk to other
susceptible indigenous wild felids (eg. the release of lynx (Felis lynx) into an area with
a resident population of wild cats (Felis sylvestris) might be unwise.
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4.

Felids, canids and pinnipeds are all susceptible to heartworm disease and should be
tested for Dirofilaria immitis by assays which detect cuticular antigen. Other
carnivores in heartworm enzootic areas may also be tested.

5.

Serology for Canidae: Carry out serology for the following diseases: canine
distemper, adenovirus, parainfluenza virus, parvovirus and leptospirosis. Previous
vaccination will influence the interpretation of the results.

For all Carnivora:
6.

Carry out complete Blood Count and PCV.

7.

Carry out serum/plasma chemistry profile.

8.

Carry out urinalysis if possible. Examine for kidney worm eggs, especially in Maned
wolf (Chrysocyon brachyurus) and for Capillaria sp.

9.

Apply tag, tattoo or microchip for identification.

10.

Deep-freeze suitably labelled serum and tissue samples.

Pre-release immunisations
Felidae
1.

Wild Felidae should be routinely vaccinated with an inactivated vaccine derived from
feline rhinotracheitis, feline calicivirus, feline Chlamydia psittaci and feline enteritis
(panleukopaenia).
[Fel-O-Vax PCT or IV (Fort Dodge Animal Health) are
satisfactory]. Vaccination should be repeated at two-week intervals for three
injections or until 16 weeks of age, then annually, when possible. Check titres, if
concerned.

2.

Canine distemper virus (CDV) has been implicated in recent deaths of lions that
showed clinical signs of distemper, on the Serengeti Plains in Tanzania. Similar
clinical findings were reported in the lions of the Masai Mar in Kenya.
Adult orphan lions in captivity were subsequently vaccinated with live attenuated
Onderstepoort strain of CDV. The results indicated that this vaccine is both safe and
8
immunogenic for lions in high risk situations.

3.

Rabies: All felids are susceptible. Use killed vaccine. [Imrab 3, (Merial Ltd.)]. See
possible legal constraint above.
Note: Check with local authorities. In some areas vaccination even with a killed
rabies vaccine is illegal.

Canidae
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1.

Canine distemper: Vaccination with new commercial recombinant vaccine is
recommended for all wild canidae. No killed vaccine is commercially available at
present. The modified live virus vaccine of canine cell line origin has been associated
with vaccine-induced distemper in wild canids. However, modified live virus primate
cell line products have provided protective titres and have not been associated with
7
vaccine-induced disease in wild canids.
Galaxy D (Schering-Plough Animal Health Corporation) appears to be the safest
modified live commercially available at present.

2.

Canine infectious hepatitis: Vaccination with canine adenovirus type 2, modified
live virus vaccine is available and can be used. There may be some risk of hepatitis
in maned wolves. The diluent portion of Adenomune-7 (Biocor, Pharmacia and
Upjohn) has a killed adenovirus type 2 antigen that can be used for maned wolves.

3.

Leptospirosis: Biannual vaccination with a multivalent bacterin is recommended.
The diluent fraction of many canine vaccines contains killed bacterins for
leptospirosis. The diluent fraction of Adenomune-7 (Biocor, Pharmacia & Upjohn) can
be used or Nobi-vacc Lepto (Intervet U.K. Ltd.) is also available.

4.

Canine parvovirus: All exotic canids should be considered susceptible. Bush dogs
(Speothos veraticus), have developed parvovirus enteritis even when vaccinated
under a regular canine regime and repeated vaccination is recommended until
protective titres develop. A suitable regime might be the use of a killed vaccine such
as Parvocine (Biocor, Pharmacia and Upjohn) for pups starting at 6-7 weeks old and
then vaccinating every 3 weeks until 16 weeks of age; pups should then be serosampled and if satisfactory titres are present, they should be given a modified live
vaccine (MLV), such as Duramune KF-11 (Fort Dodge Animal Health) at 6 months of
age and then annually. In high contact areas where parvovirus is enzootic,
vaccination every 6 months may be advisable.

5.

Parainfluenza vaccination is recommended.

6.

Rabies vaccination using a killed vaccine is always recommended [Imrab 3 (Rhone
Merieux, Inc.)]. If a killed rabies vaccine, licensed to protect domestic dogs after a
single dose, is used, the antigenic response should be checked and if found to be
inadequate, the vaccination may need to be repeated several times at suitable
intervals until protective antibody titres are found to be established.
Note: Check with local authorities. In some areas vaccination, even with a killed
vaccine, is illegal.
There is a need for further testing of rabies vaccination protocols and delivery
systems before vaccination against rabies can be relied upon to be fully protective for
2, 3
wild animals.

Procyonidae [Raccoons (Procyon lotor), coatimundi (Nasua nasua), kinkajou (Potos
flavus), red panda (Ailurus fulgens)].
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1.

Canine distemper. All are susceptible. Annual vaccination is recommended with
modified live primate cell line vaccine. Galaxy D (Shering-Plough Animal Health) is
probably the safest but a canary pox-vectored vaccine would be safer, if available for
all species other than red pandas and giant pandas (Ailuropoda melanoleuca), which
should be vaccinated only with a killed vaccine. But be aware that this may not
7
provoke a solid immunity.

2.

Feline panleukopaenia (or at least a parvovirus) has been reported in raccoons and
coatimundis. Vaccination with a killed vaccine such as Fel-O-Vac PCT (Fort Dodge
Animal Health) is recommended as it produces good FPV titers).

3.

Leptospirosis is reported in raccoons. Biannual vaccination with a multivalent
bactrin is recommended [Kavak-L (Fort Dodge Animal Health), or Nobi-vacc Lepto
(Intervet, U.K. Ltd.)]

4.

Rabies affects all species. Vaccinate with a killed vaccine. [Imrab 3. (Merial Ltd.)]
See possible legal constraint above.

Mustelidae (Mink, ferrets (Mustela sp.), weasels (Mustela sp.), otters (Lutra sp.), sea otters
4, 5
(Enhydra sp.), skunks (Mephitis sp.) etc.).
1.

Canine distemper: All members of this group are susceptible, some extremely so.
All should be vaccinated with a product NOT of ferret or canine cell line origin.
Vaccines of some avian cell lines have been shown to be safe and effective.
However, since avian cell line products, when administered to red pandas and
viverrids as part of a multivaccine have resulted in disease, possibly due to
immunosuppression and anaphylaxis, it is recommended that the canine distemper
vaccine be given separately at a reasonable interval from the other components.
A monovalent, recombinant canine distemper vaccine, canary pox-vectored, for use
in ferrets, is under development by Merial, Ltd but is as yet unlicensed. This vaccine
has undergone some preliminary clinical trials and has been found to be safe and
7
effective in a variety of wild carnivores, including some felid species.
Galaxy D (Shering-Plough Animal Health) can be used in some mustelids and
viverrids; however, it must be used with extreme caution in these species as vaccineassociated disease can occur. If unsure, always use killed CDV vaccine or canary
pox-vectored vaccine. Canine distemper vaccines, which are safe for wild carnivores
are currently under development and it is wise to consult the manufacturers.

2.

Feline panleucopaenia: All except the domestic ferret (Mustela putorius) are
susceptible. Vaccinate with killed vaccine such as domestic cat vaccine, without
respiratory virus components. When indicated, use Fel-O-Vac PCT (Fort Dodge
Animal Health).

3.

Rabies: All are susceptible. A killed virus vaccine [Imrab 3 (Merial Ltd.) has been
tested and found to be safe and efficacious and has been approved for use in
domestic ferrets by FDA. See possible legal constraint above.
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4.

Botulism: Commercially raised mink are routinely vaccinated with toxoid against
Clostridium botulinum type C. This may be unnecessary for wild mustelids prior to
release if the animals are fed appropriately during quarantine.

5.

Leptospirosis: Has been reported in mustelids. If considered a risk, vaccination with
a multivalent bacterin is recommended [Kavak-L (Fort Dodge Animal Health) or Nobivacc Lepto (Intervet, U.K.Ltd)].

Viverridae [Civets, mongooses, meerkats (Suricata suricatta) and binturongs (Arctictis
binturong)].
1.

Canine distemper: All are susceptible and vaccination with avian cell line modified
live vaccine may be carried out. However, avian cell line vaccines are no longer
available in the USA. Galaxy D vaccine (Shering Plough Animal Health) can be used
in some cases but care must be taken. It is unsafe for binturongs. If unsure, use a
killed vaccine alone, Not as part of a multivalent vaccine (see above). Binturongs
may even develop vaccine-induced disease with avian cell line vaccines, therefore
consider using killed or canary pox-vectored for this species.

2.

Feline panleucopaenia: All viverrids should be vaccinated. Use Fel-O-Vac PCT
(Fort Dodge Animal Health) when indicated.

3.

Leptospirosis: has been reported in mongooses and vaccination with multi-valent
bacterin is recommended [Kavak-L (Fort Dodge Animal Health) or Nobivacc Lepto
(Intervet, U.K. Ltd.)].

4.

Rabies: All are susceptible and should be vaccinated with a killed vaccine [Imrab 3
(Merial Ltd.)].

Hyaenidae
1.

Canine distemper: Vaccination with a killed vaccine is recommended but some
authorities believe that hyaenas are not susceptible to infections with canine
distemper.

2.

Feline panleucopaenia: Susceptibility is uncertain but vaccination is recommended.
If indicated, use Fel-O-Vac PCT (Fort Dodge Animal Health).

3.

Rabies: All are susceptible. Vaccination with killed virus vaccine is recommended
[Imrab 3, (Merial Ltd.)]. . See possible legal constraint above.

Ursidae
1.

Canine infectious hepatitis: Naturally occurring disease has been reported once in
black bears (Ursus americanus).
Vaccination should be considered when
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translocated bears might come into contact with domestic dogs. Consider using the
diluent fraction of Adenomune-7 (Biocor, Pharmacia & Upjohn).
2.

Canine distemper vaccine (killed) and feline panleucopaenia vaccine may be
required for polar bears (Ursus maritimus).

3.

Rabies: Bears are susceptible and should be vaccinated using killed virus vaccine
[Imrab 3 (Merial Ltd.)] when rabies presents a risk.

Pre-release treatment
1.

Appropriate anthelmintics
endoparasites.

should

be

administered

to

eliminate

or

control

2.

Ectoparasites should be removed by applying pyrethrin-based acaricides and/or by
administering an avermectin when necessary. For sarcoptic mange, two
administrations of an avermectin are required, followed by a negative skin scraping.
Fipronil, Frontline Top Spot and Spray (Merial Ltd.) and Imidacloprid and Advantage
(Bayer Corp.) are being used with great success in many exotic carnivore species for
ectoparasite control (especially for fleas).
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MARINE MAMMALIA 4, 5, 6
Marine mammals are sometimes found stranded on the beach, singly or in groups. It will
probably not be possible to quarantine the animals in these circumstances but a limited
health screen before return to the ocean is desirable.
Quarantine for marine mammals should last for a minimum of 30 days.
However, this period is somewhat arbitrary because knowledge of disease and disease
pathogenesis in marine mammals is incomplete.

Health screening while in quarantine
Veterinary medical history should include the following: Site of stranding, health or condition
at stranding if known, disease history (current, clinical and serologic), treatment received
during rehabilitation, documentation of physical and behavioural history and exposure to
disease.
If an animal is held with or in close proximity to other animals undergoing rehabilitation, the
disease history of pen-mates and neighbours should be considered to ensure that new
diseases have not been contracted while in rehabilitation.
Animals should be free of any therapeutic drugs for a minimum of one week prior to release
into the wild. This is to prevent drugs masking the signs of disease and to minimise the
development of drug-resistant organisms.
1.

Carry out faecal examination (direct smear, flotation and sedimentation) for
endoparasites. Both sedimentation and flotation are required to detect Otostrongylus
circumlitus.

A concentration heartworm test (Knott's procedure or Filter test) should be carried out to
screen for microfilaria. If microfilaria are seen they should be identified down to species.
A large proportion of Zalophus sp. (Californian sea lions) and Callorhinus sp. (fur seals) may
be positive for microfilaria of the inconsequential fascial worm.
2.

Carry out complete Blood Count and PCV.
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3.

Carry out serum/plasma profile.

4.

Carry out urinalysis if possible.

5.

Carry out serology and/or PCR for the following infections of Pinnipeds: Morbillivirus,
herpesvirus, influenza virus, canine parvovirus, calicivirus, leptospirosis, brucellosis
and dirofilaria. For Cetaceans: Morbillivirus, herpesvirus, and brucellosis. Serology
for morbilliviruses should include canine distemper virus, phocine distemper virus,
1, 2, 3
dolphin morbillivirus and porpoise morbillivirus).
For sea otters (Enhydra lutra): Test for brucellosis, tuberculosis, and
pseudotuberculosis.

6.

Apply tag, tattoo or microchip for identification.

7.

Ultra-freeze suitably labelled serum and tissue samples.
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RODENTIA and LAGOMORPHA 3, 4
1

(Compiled by A.W. Sainsbury )
The translocation of Lagomorphs (and their products) has proved to be a hazardous
procedure. The example of myxomatosis has shown that the spread of a virus that is benign
1
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for its host species, the South American Forest Rabbit or Tapeti (Sylvilagus braziliensis), can
be virulent for another species, the European rabbit (Oryctolagus cuniculus), and can cause
disastrous mortality in wild and captive populations, worldwide. Rabbit Viral Haemorrhagic
Disease (RVHD), and European Brown Hare Syndrome (EBHS) are also examples of
emerging virus diseases of obscure origin.
Bacterial diseases with possible zoonotic consequences and which are geographically
localised include brucellosis (Brucella suis biovar 2) and tularaemia (Francisella tularensis
biovar tularensis in North America and F. tularensis biovar palaearctica in northern Eurasia).
In countries that are free from these diseases, translocated rodents and lagomorphs should
1, 2
undergo quarantine and shown to be serologically negative before release.

Health screening while in quarantine
Quarantine for rodents and lagomorphs (hares and rabbits) should be for a minimum of 35
days during which the following procedures should be carried out.
1.

Faecal examination (direct and flotation) for endo-parasites (three samples at 15 day
intervals are recommended). Rodents and lagomorphs should ideally have three
consecutive negative faecal examinations before release.

2.

Faecal culture for Salmonella sp., Campylobacter sp., Yersinia pseudotuberculosis ,
Clostridium piliforme (three samples over ten days are recommended).

3.

Bacteriological culture of the upper respiratory tract from a nasal swab.

4.

Serological test for Encephalitozoon cuniculi in rabbits. Consider isolation and do not
release animals that are positive for antibody. Serology for Brucella suis in European
hares. Do not release animals positive for Br. suis antibodies. Consider risk of
tularaemia (Francisella tularensis) for all lagomorphs and North American and
northern Eurasian rodents. since tularaemia can be subclinical in these animals.
Details of tests to be performed are found in the OIE Manual of Standards for
Diagnostic Tests and Vaccines.

5.

For squirrels (Sciuridae), serology for parapoxvirus based on their history and origin.
Only squirrels serologically positive for antibody should be released in areas where
parapoxvirus occurs.

6.

Haematological analysis including blood count and PCV, if feasible. The volume of
blood that it is possible to collect will be dependent on body size.

7.

Serum/plasma chemistry profile, if possible.

8.

Examine blood smears for haemoparasites.

9.

Urinalysis whenever possible.

10.

Check for ectoparasites.
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11.

Examine the incisor and molar teeth for abnormalities.

12.

Carry out abdominal palpation for impaction and lesions of chronic infectious origin,
such as amyloidosis.

13.

Evaluate body condition.

14.

Identify using a microchip or with an eartag (preferably both). Eartags should be
placed in the proximal part of the ear and should be non-irritant. Toe-clipping is not
recommended.

Pre-release immunisations
1.

Rabies. If the animals are to be released in an area where rabies occurs vaccination
with a killed rabies vaccine [Imrab 3 (Merial Ltd.) is recommended.

2.

If lagomorphs are to be released where Myxomatosis, Rabbit Viral haemorrhagic
disease (RVHD, Calicivirus infection of rabbits) and/or European Brown Hare
Syndrome (EBHS) are prevalent, consider administering an appropriate vaccine.
Alternatively, test for protective antibodies. Vaccine prepared for use in rabbits
against RVHD may also be protective against EBHS.

Pre-release treatment
1.

Administer appropriate anthelmintics or other parasiticides to remove or control
endoparasites.

2.

Apply appropriate pyrethrin-type or pyrethroid acaricides and an avermectin for the
elimination of ectoparasites to reduce the possibility of tularaemia (Francisella
tularensis infection) or myxomatosis in rabbits.

3.

Consider the administration of antibiotics to reduce the severity of upper-respiratory
tract infections based on nasal culture and sensitivity testing. Tetracyclines may be
administered to decrease the severity of Mycoplasma pulmonis infection.

4.

Many rodent species are carriers of Leptospira sp. and may serve as sources of
infection for other animals and humans. The risk of transmitting leptospirosis to other
animals at the release site should be considered.
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MARSUPIALIA
(Compiled by S.A. Haigh2)
Phascolarctidae (koalas)

Health screening while in quarantine
The quarantine period should be 60 days. Koalas should be kept individually in isolation
within insect and pest proof enclosures. If possible small groups to be released together
should be kept together in quarantine. Enclosures and equipment should be disinfected
with Parvocide (gluteradehyde 100g/L and dimethyl benzyl ammonium chloride 150g/L,
Cyanamid Websters) at 1%, or Halasept (chloramine 100%, Intervet Australia) at 0.3 %.

Health screening
Koalas should be given a complete physical examination at the beginning and end of the
quarantine period including weight, normal clinical parameters, lymph node checks,
abdominal palpation, tooth wear evaluation, condition score, checks for conjunctivitis,
nasal and ocular discharges, fur staining around rump. Feet and hand pads should be
checked for sores. Faecal pellets should be normal size, shape and consistency, and
should contain fine particles. The pouch and cloaca should be checked, and in males the
penis should be everted from the cloaca and checked. The ear pinnae and canals should
be checked for wounds/infection (especially males). Any skin lesions should be scraped
for ectoparasite checks and submitted for fungal culture.
Koalas being released into Chlamydia-free populations should have two negative ELISA
1
2
tests or complement fixation tests (CFT) for Chlamydia antibody one month and at least
two months apart respectively. If positive there should be no rise in titre. For the CFT a
titre of 1:4 is considered negative. Each animal should have three consecutive negative
3
swab tests by PCR/hybridisation detection. Two swabs should be taken each time; one
from both eyes and both nostrils and one from urogenital sinus or penile urethra. The last
test should be done just prior to release. If PCR is not available, a commercial antigen
2
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detection kit such as Clearview Chlamydia (Unipath Limited, Bedford, England) can be
used. The receiving colony should have a history of regular negative antibody tests on
serum or antigen tests on swabs.
All koalas should have full blood counts and biochemistry done on entry into quarantine
and just prior to release. Azotaemia may indicate nephrosis, which is a relatively common
disease of captive koalas. Haematologic abnormalities may indicate retroviral infection
and/or myeloid neoplasia. All koalas should have at least one detailed urinalysis including
examination for calcium oxalate crystals.
There should be three consecutive, negative faecal flotations for endoparasites. Treat
with praziquantel at 5mg/kg twice (at beginning and end of quarantine) for the cestode
Bertiella obesa. Reduce access to soil ingestion. Faeces should be submitted for
complete bacteriologic examination including routine culture, anaerobic culture,
Salmonella culture, Campylobacter culture and Ziehl Neelsen staining for acid-fast bacilli.
4

Test for Cryptococcus spp. infection- use Latex Cryptococcal Antigen Test (LCAT) on
serum. Greater than 1:2 is considered positive. Two negative tests or non-rising titres are
needed.
Test both the recipient population and departing koalas for retrovirus infections with PCR5
based tests if possible. Many captive koalas are positive and it is suspected that this
virus is intrinsic within the koala genome. Release positive animals only into a positive
population.
Test the recipient and departing population for Toxoplasma gondii infection using a
6
modified direct agglutination test for antibodies . Release only negative animals into
negative populations. A large proportion of positive animals in a wild population may
indicate historic exposure to cat faeces.
Koalas may be tested for Leptospira interrogans antibodies using a microscopic
7
agglutination test . Koalas released from captivity or moved from non-paralysis tick
(Ixodes holocyclus) enzootic areas should be released into tick free areas.

Pre-release immunisations
Koalas should probably be vaccinated against Bordetella bronchiseptica using an
inactivated cell free extract of B. bronchiseptica (Canvac BB, Commonwealth Serum
Laboratories Ltd.) subcutaneously, twice four weeks apart, then annually.
Rhinitis/pneumonia complex is probably more relevant in captive koalas.

Suitability for release
If the animal has been in a captive situation for a long time or if it is captive born, a careful
assessment of the animal’s level of habituation, presence of aversion and flight
behaviours, and ability to compete for food and space should be made. It may not be
advisable to release the animal if it appears to be irreversibly habituated. All handling for
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tourism purposes etc should be stopped at least 6 months prior to release. All koalas
should be fully weaned and be 16-18 months of age prior to release or shipment to other
institutions.

Vombatidae (wombats)

Health screening while in quarantine
The quarantine period for wombats is 60 days.
Serology for herpes virus, Leptospira spp, Toxoplasma gondii antibodies (methodology as
described above) should be done. Any skin lesion should be examined carefully for the
presence of Sarcoptes scabei mites. Even if mites are not seen, and there are skin
lesions, the animal should be treated using acaricidal washes or ivermectin (Ivomec
Antiparasitic Injection for Cattle, ivermectin 10 g/L, Merck Sharpe and Dohme, or Ivomec
Liquid for Sheep, ivermectin 0.8g/L, Merck Sharpe and Dohme) (See Note under
‘Treatment Disclaimer’).
There should be three consecutive negative faecal flotations. Heavy infections of
coccidia, nematodes or cestodes should be treated appropriately. Any infestation of
Strongyloides spp should be treated.
Faeces should be submitted for complete bacteriologic examination including routine
culture, anaerobic culture, Salmonella culture, Campylobacter culture and ZN staining for
acid-fast bacilli.

Macropodidae (kangaroos, wallabies, pademelons, potoroos and bettongs)

Health screening while in quarantine
Macropods should be kept in cat, fox and rodent-free enclosures for 60 days Due to
handling difficulties unnecessary testing should be minimised.
Serum should be tested for herpes virus, Toxoplasma gondii, and Leptospira sp. infection
as per the methodology described above.
Faeces should be examined as for wombats and koalas for bacteria and there should be
three negative parasite examinations. Faeces should be particularly examined for
Strongyloides spp using a Baerman technique for larval separation.

Pre-release immunisations
Macropods should be vaccinated with a clostridial vaccine (Websters 5 in 1 Vaccine for
Cattle and Sheep, Cyanamid Websters) twice four weeks apart. Vaccination with an ovine
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foot rot vaccine (Footvax, Coopers) may provide immunity against necrobacillosis. While
in quarantine Vitamin E powder should be added to the diet.

Pre-release treatments
Heavy burdens of coccidia and nematodes should be treated appropriately. Care must be
taken when using some of the Benzimidazole drenches. This author feels that ivermectin
(Ivomec Liquid for Sheep, ivermectin 0.8g/L, Merck Sharpe and Dohme) is the most
appropriate drug for helminth parasites of macropods.

Burramyidae, Petauridae,
(Possums and gliders)

Phalangeridae,

Tarsipedidae

and

Pseudocheiridae

Health screening while in quarantine.
The quarantine period is 60 days.
Faecal examinations are as for macropods. In addition faeces should be cultured for
Yersinia pseudotuberculosis. Serum should be tested as for macropods, and Leptospira
sp may be a significant pathogen. It may be appropriate to test for Cryptococcus sp if it
has been seen within the group and/or if it has been isolated from the environment, food
trees or browse.

Peramelidae and Thylacomyidae (bandicoots and bilbies)
Health screening while in quarantine
The quarantine period is 60 days.
Faeces should be tested for acanthocephalan parasites using direct smears, as the eggs
of these parasites are difficult to detect using standard flotation and sedimentation
techniques. Echinonema sp were found to be particularly pathogenic nematodes in
Southern Brown bandicoots (Isoodon obesulus) in Western Australia (Haigh, unpublished,
1994). Ziehl Neelsen staining of faecal smears may be particularly important in this group.

Dasyuridae (carnivorous marsupials)
8

Most of the information below refers to the Western quoll (Dasyurus geoffroii) (Haigh et
al, 1994). Much of it will also be applicable to dunnarts, Antichinus sp.etc.

Health screening while in quarantine
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Testing and a quarantine period of 60 days are as for possums and gliders.
Faecal flotations for gastric and intestinal nematodes should be carried out. Strongyles
are common, while coccidia are uncommon. Positive Campylobacter sp and Yersinia sp
cultures and positive Ziehl Neelsen staining are significant in this species. Salmonella sp.
is a common isolate and may not be significant.
Serology for Leptospira interrogans, Toxoplasma gondii, and Chlamydia psittaci is
recommended. Methodology as above.

Myrmecobiidae (numbats)

Health screening while in quarantine
Numbats (Myrmecobius fasciatus) should have a 90 days quarantine period. While in
quarantine they should be fed termites known to come from areas where
acanthocephalan parasite infections have not been seen in numbats. Numbats should be
treated with ivermectin (Ivomec Antiparasitic Injection for Cattle, ivermectin 10 g/L, Merck
Sharpe and Dohme) three times at monthly intervals, or twice, at the beginning and end of
the quarantine period.
Blood samples should be taken to screen for regenerative anaemia, which has been seen
commonly in captive numbats (Haigh, unpublished). Faeces should be cultured as for
wombats. Particular attention should be paid to the presence of acid-fast bacilli in faeces.
Cultures should be negative for Salmonella, Campylobacter and Clostridium perfringens,
(Haigh, unpublished). Strongyle eggs and coccidia are common in wild numbat faeces
(Haigh, unpublished).
Serology for Leptospira interrogans, Toxoplasma gondii, and Chlamydia psittaci is
recommended. Methodology is as above.

MONOTREMATA
Ornithorynchidae (platypus)

Disease screening while in quarantine
Monotremes should be isolated in quarantine, confined in an appropriate enclosure for 90
days.
Diseases that have been seen include Mucor amphibiorum skin infection, adenovirus
infection, Leptospira interrogans infection, and Aeromonas hydrophila and Salmonella sp
infection.
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Blood smears should be screened for the red blood cell protozoan parasite Theileria
ornithorhynchi and plasma should be checked for trypanosomes. Treat with Trivetrin
(Jurox, Trimethoprim/Sulphonamide 40mg/ml/200mg/ml) 5mg/kg I/M to reduce the
shedding of coccidial oocysts in faeces.
Serum should be screened for Toxoplasma gondii antibody.
Treat heavy burdens of Ixodes sp ticks with ivermectin (Ivomec Antiparasitic Injection for
Cattle, ivermectin 10 g/L, Merck Sharpe and Dohme) S/C at 200ug/kg as they are
probable vectors of Theileria.

Tachyglossidae (echidnas)

Health screening while in quarantine
The quarantine period should be 90 days.
Enclosures should exclude the definitive hosts of Spirometra eranacei (dogs, dingoes,
cats and foxes).
Bleed to screen for anaemia. Theileria, Babesia and Anaplasma have occurred in
clinically normal animals. Treat for coccidia prophylactically while in quarantine. The
following potential disease agents have been seen: herpes virus, adenovirus, Salmonella
sp. Mycobacterium sp has caused fatal generalised disease. Microsporum gypseum has
been seen in echidnas with broken spines.
Three faecal floats should be negative for large numbers of nematodes. Treat ticks with
ivermectin (Ivomec Antiparasitic Injection for Cattle, ivermectin 10 g/L, Merck Sharpe and
Dohme) injection as they may be associated with dermatitis and anaemia.
Poisonous plants
Marsupials from the East Coast of Australia that are known not to be resistant to the
Sodium fluoroacetate-bearing Gastrolobium sp and Oxylobium sp., plants, which occur
predominantly in Western Australia, should be released into areas that are free from these
plants.

Chiroptera (Bats)
The following information is taken from personal communication with Dr. Hume Field of
the Department of Primary Industries, Animal Research Institute, Marooka, Qld 4105,
Australia.
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Megachiroptera-Pterapoidae (flying foxes, fruit bats, blossom bats)
Screening of bat populations in the Australasian region is on-going. In wild populations of
pteropids evidence of infection with Hendra virus (equine morbillivirus), Australian bat
lyssavirus (ABL), Menangle virus and unidentified flavivirus/es (Australian and Papua New
Guinean bat populations) have been found. A newly described paramyxovirus (Nipah
virus) has recently been found in Malaysian bat species.

Microchiroptera (insectivores)
Some species have evidence of infection with ABL.

Health screening tests for Chiroptera
(Most tests are available through the Animal Research Institute, see address above).
Serum neutralisation tests (SNT) are used as the gold standard diagnostic test for
Japanese encephalitis, Hendra virus, Menangle virus and Nipah virus. A fluorescent
antibody test (FAT) is used to screen for ABL antigen in brain and salivary gland tissues
and a rabies rapid fluorescent focus inhibition test is used to identify circulating antibodies
to ABL. A competitive ELISA is used to screen for antibodies to the flavivirus serogroup
prior to a specific SNT for Japanese encephalitis.
To the author’s knowledge no viruses that have not been seen in the wild, have been
detected in captive bats. Screening of captive bats prior to release or translocation would
involve testing the recipient population and the bats to be translocated for the above
viruses, and attempting to release naïve bats into virus free wild populations or positive
bats into similar positive populations.

Pre-release immunisations
No controlled trials have been conducted on bat species. However, vaccination of bats
destined for release into wild populations will potentially confound the interpretation of
sero-surveillance of wild populations for evidence of natural infection and should therefore
be avoided (Hume Field, pers. comm.).
Dr. Christopher Bunn (Commonwealth DPIE) has produced a document for the Australian
Veterinary Plan on disease strategy for ABL in domestic animals and captive bat
populations.

58

MARSUPIALIA (NEW WORLD)
Opossums (Didelphis virginiana)
Opossums in North and Central America appear to have a very low prevalence of rabies
when compared with eutherian mammals (e.g. coyotes, foxes, skunks and raccoons).
Sarcocystis infestation may be a significant translocation concern. Opossums are the
primary hosts for the sarcosporidian (Sarcocystis neurona) that causes Equine Protozoal
Myelitis and are implicated in the spread of this disease. Opossums are also implicated in
the occurrence of this neurological disease in captive cervids (e.g. white-tailed deer).
Unfortunately, at present there is no serological test that could be used in a quarantine
evaluation for this protozoon. If translocation of New World opossums to a “sarcosporidia9
free” area is proposed, these facts should be borne in mind.
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PHARMACEUTICAL COMPANIES AND LABORATORIES MENTIONED IN THE
MARSUPIALIA CHAPTER
Commonwealth Serum Laboratories Ltd., Parkville, Victoria 3052, Australia.
Jurox Pty. Ltd., Unit 22/Block B, Slough Business Park, Holker St., Silverwater, N.S.W
2128, Australia.
Cyanamid Websters Pty Ltd., 23 Victoria Ave, Castle Hill, N.S.W 2154, Australia.
Intervet (Australia) Pty Ltd., Unit 3, 4 Gladstone Rd, Castle Hill, N.S.W, Australia.
Mallinckrodt Veterinary (Coopers Brand), 9 Ferntree Pl, Notting Hill, Victoria, 3149
Australia.
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Merck Sharpe and Dohme, (Aust). Pty. Ltd, 54 Ferndell St, South Granville, N.S.W. 2142,
Australia.
Mount Pleasant Laboratories, Department of Primary Industries and Fisheries, Kings
Meadows, Tasmania, Australia, c/o Dr. David Obendorf.

TREATMENT DISCLAIMER
The drugs listed in the above report are not registered for use in Australian native species.
They may therefore result in undesirable reactions or even death.
The mention of a specific drug vaccine or manufacturer by name in this text does not
imply a recommendation by the author, editor and publishers but is merely a suggestion of
what is available and where it can be found. Always consult the manufacturers and
wildlife specialists before using these drugs.
It is recommended that a Veterinary Surgeon obtains and administers any Schedule 4
drugs in accordance with the national Veterinary Surgeons Act and the Poisons Act.
Note: There have been occasional problems when administering Ivomec Antiparasitic
Injection for Cattle to some native Australian species. This author therefore recommends
using the oral sheep preparation where possible. With echidnas, it is possible to give oral
medications at the end of gas anaesthesia via a catheter and syringe, just as the animal is
waking up and its mouth can be opened.

AVES
Health screening while in quarantine
Quarantine should last for 30 days. But remember that some small species may die if
closely confined for as little as 24 hours. Birds at high risk of Newcastle Disease should be
quarantined for 60 days.
The following are recommendations for appropriate testing procedures for diseases of birds
while held in quarantine. When large numbers of birds of the same or related species are
held as a flock or contiguous group, a series of random faecal samples should be examined.
The serology screen should be appropriate for the disease profile of the species
1, 2, 3
concerned.
1.

Faecal examination, direct and flotation, for trichomonads, other motile protozoa and
coccidia, gizzard worms of ducks and geese and tapeworms in small passerines.
Stain faecal smear (Gram) and examine for Candida sp. and Clostridia sp., stain
faecal smear (Ziehl-Neelsen) for acid fast bacteria but remember that Mycobacterium
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avium may be shed only sporadically and that thus a negative smear is not
significant. For the diagnosis of avian tuberculosis a liver biopsy may be more useful.
2.

Check for ectoparasites, especially Amblyomma sp. ticks that can be vectors of
cowdriosis-heartwater. If present, treat with an acaricide.

3.

Carry out appropriate serological tests for chlamydiosis (psittacosis) and if positive,
confirm by cloacal swab cultures. If culture is positive, the bird must be treated if of
conservation value or destroyed if not. Treatment, which in some countries is
mandatory for psittacine birds in quarantine, is lengthy, consisting of 45 days
continuous feed medication with chlortetracycline.

Note: Chlamydiosis (Psittacosis /ornithosis) is a dangerous zoonosis.
4.

Faecal cultures for Salmonella sp. and Campylobacter sp.

5.

Collect samples (choanal and cloacal swabs) for virus isolation from all incoming
birds. Samples may be pooled from members of a flock. Samples for virus isolation
should be routinely collected from all birds, which die in quarantine. All virus isolation
tests should be negative in birds destined for release or entry into captive breeding
flocks.

6.

Carry out complete Blood Count and PCV.

7.

Carry out serology/ELISA, as appropriate, for aspergillosis, Chlamydia sp.,
paramyxovirus 1 (PMV-1), PMV-2, PMV-3, Eagle herpes virus, pigeon and raptor
viruses, adenovirus, avian pox, avian influenza, mycoplasmosis and, for psittacines,
“beak and feather virus” disease, Pacheco's disease and polyoma virus disease. All
ELISA tests should be negative in birds for release or entry into captive breeding
flocks.

8.

Check raptors, Otidae (bustards) and Columbidae for oral trichomonosis.

9.

Examine blood smears for avian malaria, Babesia sp. and Leucocytozoon sp.

10.

Carry out endoscopy for aspergillosis in rare and valuable species.

Note: Birds destined for release into a Newcastle disease-free area should not
4
originate from an area where Newcastle disease is present.
Vaccination of exotic avian species against Newcastle disease is not
recommended.
Newcastle disease has zoonotic implications. Clinical signs reported in humans are
mild to severe conjunctivitis, general malaise and sinusitis, which usually resolve after
7-20 days. The wearing of goggles, gloves and a facemask when performing a
postmortem examination on a bird is recommended.
Note: Translocation and re-Introduction projects for birds of all species, but especially
psittacines, must always include very strict health screening and disease detection
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measures. Some veterinary authorities are strongly opposed to the use of birds bred
or held in captivity for re-introduction projects, believing that the disease risks are too
great. Where possible, the birds should not leave their country of origin and captivebred birds should not be exposed to non-indigenous species.
Birds bred or maintained for long periods in captivity may, like some mammals,
develop behavioural aberrations that can interfere with their ability to mate, brood
eggs and rear young. Such birds should be excluded from re-introduction
programmes.
Of special concern is the health risk posed to wild populations of psittacines by
diseases acquired by birds bred in aviaries or kept in captivity and which may
become the subject of release projects. Birds maintained in captivity may be
exposed to multiple diseases that may or may not be exotic to their native habitat.
The main diseases that are carried by captive psittacines and could seriously
threaten wild psittacine populations (and some other species) if inadvertedly
introduced include:
Polyoma Virus
This viral disease is a threat to neonatal New World and some Old World psittacines.
The virus may be a commensal infection of Australian cockatoos. It can cause very
serious losses in New World species such as macaws. A PCR probe exists and
there are known to be occult and intermittent excreters of the virus.
Psittacine Circovirus (PBFD) or Psittacine Beak and Feather Disease
This virus primarily affects Old World and Australian species. Infection results in
immunodeficiency and death. It is believed that the virus may have been introduced
into Australia from Africa by aviary-bred birds. A PCR probe exists but may not
identify all carriers.
Psittacine Herpesvirus (Pacheco’s Disease)
This disease affects both New and Old World species. It is enzootic in South
America and was first described in Brazil. Pacheco’s Disease can produce very
severe losses in birds stressed by crowded confinement. PCR probes are under
development.
Chlamydia, Psittacosis or Ornithosis
This is a common rickettsial disease that can affect all bird species and some other
vertebrates, including humans. Carrier status may be difficult to detect but PCR
probes and serological tests exist. Treatment is mandatory in some countries (see
above).
The following diseases create asymptomatic carriers for which no known tests exist
at present. All are extremely dangerous.
Proventricular Dilatation Disease (PDD)
This disease can affect all species of psittacines and many non-psittacine species
such as passerines and rhamphastids. It is believed to be viral and causes
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irreversible neural damage to birds of all ages. The carrier state cannot yet be
detected.
Papillomatosis
This disease is believed to be of viral origin and affects both New and Old World
birds. The disease causes verrucose fleshy growths on the mucosae and can affect
7, 8, 9
general health and reproductive capacity.
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It has been stated that most translocation projects involving amphibians and reptiles have
not been successful and that they should not be advocated as conservation techniques.
Consequently, if and when it is decided to release confiscated or unwanted pet reptiles into
the wild, it is particularly important to screen them carefully, so as to minimise the risk of
1
introducing a dangerous infection into the wild population.

Health screening while in quarantine
Quarantine for reptiles should last for 90 days. Quarantine facilities should be adequate for
the thermal requirements of the species under quarantine and allow for thermo-regulatory
behaviour.
6

1.

Faecal examination, direct and flotation, for protozoan (especially Cryptosporidia sp.
4
and Amoeba sp.) and metazoan parasites. Three or more consecutive tests should
be negative.

2.

Culture faeces for Salmonella sp.

Note: Since > 80% of reptiles can test positive for Salmonella sp. evidence of infection may
not preclude release.
3.

Carry out complete Blood Count and PCV.

4.

Examine blood smears for haemoparasites.

5.

Swab/nasal wash and examination for Mycoplasma sp. and Mycobacteria.sp.

Note: Check the wild, recipient chelonian population for enzootic mycoplasmal infection,
too. If the wild population is already infected, it may be unnecessary to disallow the
release of infected chelonians.
6.
7.

Serology for antibodies of Mycoplasma sp.and herpes virus for chelonians (especially
2, 5
Testudo hermanni and T. graeca) and orphidian paramyxovirus for reptiles .
Check for tick infestation, especially Amblyomma sp. that can be vectors of
cowdriosis-heartwater. If present, treat with an acaricide.

Note: Green sea turtles (Chelonia mydas) which have been treated surgically for fibropapillomatosis should be released only in the area in which they were found, since
this condition seems to occur in certain defined geographic areas.

Crocodylia
3
(Compiled by F. Huchzermeyer, IUCN/SSC Crocodile Specialist Group).
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Pre-release quarantine for farm–bred crocodylia, beyond the time required to carry out a
clinical examination, apply specific serological tests and where appropriate, pre-release
treatment for parasitic worms, is considered to be stressful and unnecessary.
Wild populations are often reservoirs of the known crocodile-specific diseases: caiman
pox, crocodile pox, adenoviral hepatitis, chlamydiosis, mycoplasmosis (arthritis) and
coccidiosis.
Most of the specific diseases of crocodylia listed above are enzootic in wild populations
and wild crocodiles thus present a greater danger to captive (farmed) crocodiles than the
reverse.
Unfortunately, except for chlamydiosis, there are no serological tests for the above
diseases. Tests for mycoplasmosis might be possible if the relevant test antigens could be
prepared. Pre-release testing for chlamydiosis in Nile crocodiles and clinical examination
for mycoplasmosis in Nile crocodiles and American alligators should be carried out as a
routine.
Crocodile coccidial oocysts are extremely fragile and are rarely detected in faecal
flotations or direct smears. However, coccidiosis is considered to be a major disease of
8
farmed crocodiles in Zimbabwe.
The examination of blood smears from crocodiles serves little purpose since the known
blood parasites of crocodiles appear to be harmless.
Gastrointestinal nematode infections are usually asymptomatic in crocodiles but may
occasionally be associated with disease. Infection with Dujardinascaris sp. may cause
8, 11
disease and can be associated with gastric ulceration and runting in hatchlings.
Nematode larvae in the muscles of slaughtered Nile crocodiles from farms in Zimbabwe
have been tentatively identified as Trichinella spiralis nelsoni but this identification has
since been questioned and it has been suggested that they may represent a new taxon of
Trichinella. The distribution of T.spiralis is cosmopolitan and it can transmit to domestic
9
livestock and humans.
Pentastomes often occur in crocodilians in great numbers, both as adults and also as
larvae and nymphs. Pentastomiasis is regarded as a major disease on crocodile farms in
10
Australia.
Pre-release clinical examination of crocodiles should exclude cases of dermatitis.
If farmed crocodilians are to be released into the wild, a health certificate covering the
farm of origin and a clinical examination of the animals to be released should be obtained.
No runts, animals in poor condition or with visible abnormalities should be released.
Crocodiles from farms with a recent history of disease and mortality should not release
animals into the wild and juvenile crocodiles which have been fed on river fish should be
treated with an anthelmintic before release.
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When possible, release should not take place in winter or during the cold months of the
year.
The release area should be ecologically correct for the age group to be released and the
behaviour and movement patterns of the species concerned should be considered.
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6
(Compiled by A. A. Cunningham, P. Daszak & A. D. Hyatt

Infectious disease threats to amphibians
Threats to wildlife of infectious disease entities brought about by anthropogenic factors are
1, 2
being increasingly recognised.
Although increasing at a rapid rate, knowledge of the
identity and epizootiology of infectious diseases that affect amphibians is relatively poor.
However, a number of diseases has been recognised which could potentially be devastating
should they be introduced to naïve populations. Two of these, amphibian chytridiomycosis
and ranavirus disease, have recently emerged as major threats to the survival of wild
3
amphibians on a global scale, possibly via the activities of humans. Although further
investigations are required before such hypotheses are substantiated or refuted, it would be
wise and prudent to ensure measures are taken to minimise the threats of introduced
disease when working with, and in particular when translocating, amphibians, regardless of
the purpose of the work.
As with all animals, when considering the translocation of amphibians, both the source and
destination of the animals must be taken into account. The longer an animal is maintained
in captivity, for example, the greater the chance it will have an altered complement of
symbiotic and parasitic flora and fauna to that found in its natural habitat. The ultimate goal
of screening animals prior to translocation is to prevent the co-introduction of alien
organisms and to maximise the chance success rate of the project. As it is impossible
(through lack of knowledge, funds, etc.), and probably impractical even if possible, to ensure
this is done to a final conclusion, pragmatic alternatives have to be taken.
4
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Quarantine period and general screening to determine suitability for release
Animals to be translocated should be quarantined, either prior to shipment, in a holding area
on arrival, or preferably both, prior to release. The time of this quarantine period is arbitrary
given the lack of knowledge of amphibian diseases, but should certainly be no less than 30
days.
During this holding period, every animal should be examined for obvious signs of ill-health.
The presence of ill-health (presence of lesions, poor body condition, etc.) automatically
renders an animal unfit for release on welfare grounds.
Animals should be examined for subclinical presence of parasites (taken here to include
eukaryotic organisms, prokaryotic organisms and viruses). The presence of parasites does
not necessarily rule out animals for release, provided the parasites present are naturally
enzootic to the area of release. If there is a large number of animals, it may not be
necessary to examine each animal for evidence of parasites, provided a statistically
meaningful number are examined from each batch within parasite-transmission contact
(defined as contact close enough for the transmission of a specific parasite to occur
between hosts and for a long enough time period, e.g. pre-patent period for certain
nematodes, to enable such transmission to be detected).
Any animal that dies during the pre-release quarantine period must be necropsied and
examined for evidence of disease, including specific histopathological examinations and
culture for iridoviruses and cutaneous chytrids.
Measures should be taken, within reason, to prevent the release of animals into an area
where disease to which they are not immune is enzootic. There should, therefore, be some
knowledge of the parasite status of animals in general, and amphibians in particular, at the
release site, for example by conducting necropsies on animals found dead or killed (such as
those hunted/fished) in the area. If animals of the same species are already present at the
site of release then, if possible, a statistically meaningful number should be examined to
enable a reasonably accurate picture to be gained of the endemic parasite flora and fauna.
The presence or absence of ranaviruses and cutaneous chytrid fungi, in particular, must be
determined prior to the release of the translocated animals.
Given the dangers of potentially catastrophic epizootic ranavirus disease or cutaneous
chytridiomycosis, animals harbouring these organisms must not be used for translocation.
Sites where evidence of ranavirus disease or cutaneous chytridiomycosis are found must
not be used for the release of amphibians. There are many different types of amphibian
ranavirus and this may also be the case for amphibian chytrid fungi. Therefore, even where
evidence of such a parasite is found in both translocated animals and release sites, it is
strongly recommended that caution be erred upon and no release be conducted.
Finally, it should be remembered that the alteration of the exposure to parasites following
the release of translocated animals can have unforeseeable consequences, including
1, 2
harmful effects on genera, orders or classes other than those of the target animals.
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Minimum screening required
These procedures should be carried out as indicated above for live animals destined for
translocation and, where possible, during necropsy of animals that have died during the
translocation period, or those collected from target release sites.
No immunisations are currently available for ranavirus disease,
chytridiomycosis or other significant infectious diseases of amphibians.

cutaneous

1. Cutaneous chytridiomycosis
Diagnosis is by identification of characteristic intracellular flask-shaped sporangia and
4, 3, 5
septate thalli within the superficial epidermis.
The most reliable technique is
histology, either of a toe-clip taken from a live animal, or of toe-clips and ventral skin (from
the pelvic “drink” patch) taken from a necropsied animal. Full protocols for examination
6
and histology are given in a web-published article, available at the “Amphibian diseases
home page” run by R. Speare of the James Cook University, Australia
(http://www.jcu.edu.au/dept/PHTM/frogs/ampdis.htm). Wright’s- or Diff-Quik- (Difco
5
Laboratories, Detroit, Michigan, USA) stained smears of skin scrapings or impression
(touch) smears of ventral pelvic (“drink”) patch skin stained with Wright’s or Diff-Quik are
also potentially useful, however smears are less reliable than histologic analysis.
Research is currently underway to develop ELISA and other antibody-based tests and
PCR-based tests; polyclonal antibodies against chytrids (not Batrachochytrium
dendrobatidis specific) are available from the Australian Animal Health Laboratory
(Geelong Australia) together with an immunoperoxidase protocol.

2. Ranaviruses
Animals exhibiting lesions or clinical signs consistent with the range observed in ranavirus
7, 8
disease of anurans and urodeles
should be necropsied and viral presence determined
by culture in commercially available cell lines. Due to differential culture characteristics of
various ranaviruses, a range of cell lines, including fish and amphibian cells, should be
used. Cell lines in which ranaviruses have been successfully cultured include fathead
minnow (FHM) epithelial cells (European Collection of Animal Cell Cultures No. 88102401),
Rana pipiens embryo fibroblast cell line (ICR-2A, ECACC), epithelioma papulosum cyprini
cells (EPC cells, Life Technologies, Grand Island, New York, USA), Chinook Salmon
Epithelial (CHSE) cells and Vero cells. Culture should be conducted at between 25 and
o
27 C as this appears to be the optimum range for ranavirus growth. Ranaviruses do not
o
grow at temperatures above 30 C. The cytopathic effect (CPE) produced by ranaviruses
depends on the virus species and the cell culture used, but typical ranavirus CPE in cell
monolayers consists of discrete, progressive plaques of rounded-up and sloughing cells.
Details (cells, temperature and procedures) for the isolation of ranaviruses can be found in
the Office International des Epizooties (OIE) "Diseases Manual for Aquatic Animal
Diseases".
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Virus can be identified directly in tissues or in cell cultures by electron microscopy with the
examination of ultra-thin sections and the examination of negative-stained particulate
9, 10
samples.
Unfortunately, no general serological test has yet been evaluated for the
detection of antibodies within susceptible animals. Specific antibody detection assays
exist for Bufo marinus and these assays can be adapted to a general competitive ELISA
but the sensitivity and specificity of the latter is not known. A large number of ranaviruses
11
have now been examined and the data show that the OIE accepted EHNV antigen11
capture ELISA can be used to detect all known ranaviruses. Further details of these
ELISAs are available from Dr Alex Hyatt, CSIRO Australian Animal Health Laboratory,
Geelong, Victoria, Australia. Ranaviruses can also be detected (in-vivo and in-vitro) by
12, 13
PCR.

3. Erythrocytic iridoviruses
These can be identified by light microscopy of blood cells on air-dried, Giemsa-stained
blood smears, with follow-up electron microscopy if intracellular inclusions are found.

4. Enteric and pulmonary helminths
The presence of helminth eggs or larvae can be detected using standard methods for light
microscopical examination of wet faecal smears.

5. Enteric protozoa
Enteric protozoa can be detected using light microscopy of wet faecal smears. It should
be remembered that a range of commensal, and possibly also symbiotic, protozoa may be
found using this technique, in addition to parasitic organisms.
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There are unquantifiable disease risks for releases involving wild fish in direct
translocations. Although these need to be reflected in stringent quarantine requirements,
quarantine by itself, in such circumstances, can only act as an aid to disease prevention
and should not be considered as a guarantee. Full consideration should be given to the
need for any such movement and if deemed necessary it is essential to develop a
comprehensive veterinary risk assessment for each specific case, with quarantine
protocols directed at identified specific risks, in consultation with local veterinary expertise.

Captive releases. Salmoniformes
Salmonid fish have been bred in captivity for release in rehabilitation programmes for over
a century.
The following are the minimum recommendations for appropriate testing procedures of
captive-bred salmonids for the major diseases of salmonid fish held in quarantine prior to
release. These requirements should be applied in addition to those imposed by
adherence to guidelines such as of the International Aquatic Animal Health Code
produced by OIE.

General health measures
Fish selected to enter a pre-release quarantine facility are best sourced from a facility with
good quality veterinary health programmes in place. Prior disease history should be
thoroughly evaluated before fish are entered into any release programme.
Further, any disease problems encountered during the quarantine period should be
thoroughly investigated by the quarantine facility’s veterinarian and decisions regarding
release should include the evaluation of the results of such investigations as well as preentry disease history. Parasites - Gill squash, skin scrape and faecal examinations should
be carried out to establish the major ecto- and endo-parasites associated with the fish.
Treatment for identified parasites should be applied within the quarantine period in
accordance with local veterinary advice.

Viral diseases
The recognised means of preventing spread of fish viruses is to avoid the contact of fish
and virus. This is best done when fish are sourced from areas recognised as being free
from these diseases.

Bacterial diseases
Bacterial kidney disease - Fish for release should be sourced from an area recognised as
free from this disease.
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Furunculosis and Enteric Redmouth - Vaccination is recommended (use an oil adjuvant
based vaccine for furunculosis). Time should be allowed within quarantine to include
development of sufficient protection before release, in accordance with the manufacturers’
instructions.

Fungal diseases
A number of species of fungi are associated with disease processes in fish. However,
although fungi are infectious agents the aetiology of many fungal diseases includes stress
(including normal physiological endocrine-driven changes in some instances), and
environmental, husbandry and management factors, as predisposing causes. Many fungal
agents are ubiquitous in nature and prevention of disease-spread during fish movements in
directed at prior attention to optimum husbandry of fish in captivity, minimising stressors,
culling and/or strategic therapy, as advised by local veterinary expertise.
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Sources of Vaccines and Pharmaceuticals
Note: The mention of the names of pharmaceuticals, vaccines and their manufacturers in
this publication does not imply recommendation. It is merely a guide as to what products
are available and their sources. Many of the drugs and vaccines mentioned here are not
licensed for use in wild animals and their safety and efficacy are untested. In addition,
veterinary drugs and vaccines are continuously undergoing development and improvement.
Veterinarians are therefore strongly advised to consult manufacturers and specialists
before using the products mentioned in this booklet.
It is important to remember that veterinary pharmaceuticals and vaccines are produced
and marketed worldwide and may be manufactured and distributed in different countries
under different names. The head office of the manufacturer may be in the U.S.A. or
Europe or elsewhere and will always advise on the availability of products in other
countries.
! Merial Ltd. (formerly Rhone Merieux Inc.)
115 Trastech Drive,
Athens, GA 30601
United States of America
Tel: 1(800) 255 6144 or 1(888) 637 5251
Imrab3 (Killed Rabies Vaccine)
Eprinomectin (Eprinex) (ruminant anthelmintic)
Fipronil, Frontline, Top Spot and Spray (Ectoparasite control)
! Butler,
4344 Federal Drive, Suite 104,
Greensboro, NC 27401
United States of America
Tel: 1(800) 551 3861

Fax: 1(888) 329 3861

Various canine, feline, equine, bovine and porcine vaccines
! Pfizer Animal Health
PO Box 747029
Pittsburgh, PA 15274-7029
United States of America

Pfizer Ltd.
Ramsgate Road, Sandwich
Kent CT13 9NJ, U.K.
Tel: 1(800) 733-5500

Leptoferm 5, BratiVac-6 (Leptospira vaccines)
Doramectin (Dectomax) (Ruminant anthelmintic)
! Bayer Corporation, Animal Health
PO Box 751772
Charlotte, NC 28275
United States of America

Tel: 1(913) 631-4800

Vision 7, Vision 7 with SPUR (Clostridial bacterin-toxoid for all ungulates)
Super-Tet with Havlogen (Tetanus vaccine)
Prestige with Havlogen (Killed equine herpes virus vaccine)
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Imidacloprid, Advantage (Ectoparasite control)
! Fort Dodge Animal Health
9401 Indian Creek Parkway
Ste. 1500
Overland Park
KS 66210
United States of America

Fort Dodge Animal Health
Flanders Road
Hedge End
Southampton SO30 4QH
U.K.

Triangle 3 (combined IBR, BVD and P13 vaccine)
Fel-O-Vac (Inactivated)
Cydectin (Moxidectin) (ruminant anthelmintic)
Duvaxyn IE and IET
Fluvac (Equine influenza vaccine)
(Equine Influenza and tetanus
Encephaloid (Killed EEE and WEE vaccine)
vaccines)
Fel-O-Vac PCT and Fel-O-Vac IV (3-way killed vaccine for feline rhinotracheitis, calicivirus
and panleucopaenia)
Duramune KF-11 (Modified live canine parvovirus vaccine)
! SmithKline Beecham Animal Health
West Chester
PA 19380
United States of America
Albendazole and Valbazen (Flukicides)
! Merck Agvet
Division of Merck and Co. Inc.
P.O. Box 2000
Rahway, N.J. 07065
United States of America
Clorsulon and Curatrem (Flukicides)
Ivermectin (Ivomec) (ruminant anthelmintic)
! Schering-Plough Animal Health Corporation
P.O. Box 3113
Omaha, NB 68103
United States of America
Permectrin 11 (Pyrethrin acaricide)
! Colorado Serum Company
4950 York Street
Denver, CO 80216
United States of America
Anthrax vaccine
! Haver-Lockhart
Shawnee
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KS 66201
United States of America
Praziquantil (Droncit) (Intramuscular anthelmintic for Echinococcosis)
! Biocor, Pharmacia and Upjohn
7000 Portage Road
Kalamazoo, MI 49001
United States of America
Adenomune-7 (Live vaccine for canine infectious hepatitis)
! Intervet U.K.Ltd.
Science Park
Milton Road
Cambridge CB4 0FP
U.K.
Nobi-Vacc Lepto (Inactivated
Icterohaemorrhagiae antigens)

vaccine

containing

Leptospira

canicola

and

L.

! Hoechst Rousel Vet Ltd.
Walton Manor
Walton, Milton Keynes
Bucks. MK7 7 AJ
U.K.
Heptavac (Clostridial vaccine for Artiodactyla)
! United Vaccines Inc.
P.O. Box 44220
Madison
WI 53744-4220
United States of America
Vaccines for mink, ferrets and foxes
Two useful sources of relevant information are:
1.

Soorae, P.S. and Seddon, P.J. (Eds). 1998. Re-introduction Practitioners Directory.
Published jointly by the IUCN Species Survival Commission’s Re-introduction Specialist
Group, Nairobi, Kenya and The National Commission for Wildlife Conservation and
Development, Riyadh, Saudi Arabia. 97pp.

Copies of the above Directory are available from: The Secretary-General, National
Commission for Wildlife Conservation and Development, Post Box 61681, Riyadh 11575,
Kingdom of Saudi Arabia. Tel.(966-1) 441 8700, Fax. (966-1) 441 0797.
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2.

American Zoo and Aquarium Association (AZA), Reintroduction Guidelines. Copies of
these guidelines are obtainable from: Dr. Benjamin Beck, National Zoological Park,
Smithsonian Institution, Washington, D.C. Email: bbeck@nzp.si.edu.

USEFUL ADDRESSES
This list of addresses that follows does not pretend to be comprehensive. Addresses and
telephone numbers can change and where possible should be checked before use.

1.

CSIRO Division of Wildlife and Ecology
P.O. Box 84
Lyneham, ACT 2602
AUSTRALIA

2.

CSIRO Division of Animal Health
Long Pocket Laboratories
Private Bag, No. 3
Indooroopilly, QLD 4068
AUSTRALIA

3.

Non-Domestic Register of Pathology
Taronga Zoo
P.O. Box 20, Mosman, NSW 2570
AUSTRALIA

4.

Marine Animal Resources Centre
69 Main Street
Pialba, QLD 4655
AUSTRALIA

5.

Chief Central Veterinary Laboratory
Frome Road
G.P.O. Box 1671, Adelaide, SA
AUSTRALIA

6.

University of Melbourne Veterinary Clinical Centre
Princess Highway
Melbourne, VIC. 3030
AUSTRALIA

7.

Animal Health Division
Dept. of Agriculture
Jarrah Road
South Perth, WA 6151
AUSTRALIA

8.

Department of Agriculture
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Mount Pleasant Laboratories
P.O. Box 46
Launceston, TAS. 7250
AUSTRALIA
9.

Australian Association of Veterinary Conservation Biologists (AAVCB)
C/o The Australian Veterinary Association
134-136, Hampden Road
Artarmon, NSW 2064
AUSTRALIA

10.

Institut National de Recherches Veterinaires
Groeselenberg, 99
B-1180 Bruxelles
BELGIUM

11.

Centre de Medicine du Gibier
Universite de Liege
Faculte de Medicine Veterinaire
Sart-Tilman 4000 Liege
BELGIUM

12.

Brazilian Association of Wildlife Veterinarians (ABRAVAS)
Fundação Parque Zoologico de São Paulo
Ave. Miguel Stefano 4241 Agua Funda
04301 São Paulo SP
BRAZIL

13.

Asociacion Latinoamericana de Medicos Veterinarios en Fauna Silvestre
Edificio Batallon Colorados Piso 11 Apto 04
Calle Batallon Colorados N.24
Centro La Paz
BOLIVIA

13.

National Wildlife Research Centre
Canadian Wildlife Service
Environment Canada
100 Gamelin Boulevard
Hull, Quebec, K1A 0H3
CANADA

14.

Canadian Cooperative Wildlife Health Centre (CCWHC)
Department of Veterinary Pathology
Western College of Veterinary Medicine
University of Saskatchewan
Saskatoon, SK S7N 0W0
CANADA

15.

Canadian Association of Zoo and Wildlife Veterinarians
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2355 Corydon Avenue
Winnipeg
Manitoba R3P 0R5
CANADA
16.

Central Veterinary Laboratory
Department of Veterinary Sciences
Athalassa, Nicosia
CYPRUS

17.

State Veterinary Institute
Department of Virology
Rantirovska 93
586 02 Jihlava-Horni Kosov
CZECH REPUBLIC

18.

National Veterinary Laboratory
2 Hangovej
DK-8200 Aarhus
DENMARK

19.

Veterinary Research Institute
Dokki
EGYPT

20.

Veterinary Research Laboratory
Department of Agriculture and Food
Abbottstown
Dublin 15
EIRE

21.

National Veterinary Institute
P.O. Box 19
Debre Zeit
ETHIOPIA

22.

Finnish Forest Research Institute
Department of Forest Ecology
P.O. Box 18
SF-01301 Vantaa
FINLAND

23.

Institut Pasteur
28 rue du docteur Roux
75015 Paris
FRANCE

24.

Tel: (33-1) 4568 8895
Fax :(33-1) 4568 8639
lepas@pasteur.fr

FAO World Reference Laboratory for Peste des Petits Ruminants
CIRAD-EMVT
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Campus International de Baillarguet
Montferrier-sur-Lez
BP. 5034, Cedex1, Montpelier 34032
FRANCE
25.

26.

AFSSA Alfort
Unite d’Epidemiologie
22 rue Pierre Curie
BP 67
94703 MAISONS-ALFORT Cedex
FRANCE
Office International des Epizooties (OIE)
12 rue de Prony
75017 Paris
FRANCE

Tel. (33-4) 6759305
Fax. (33-4) 67593798
diallo@cirad.fr

Tel. (33-1) 4977 1333
Fax. (33-1) 4368 9762

Tel. (33-1) 44151888
Fax. (33-1) 42670987
oie@oie.int

27.

Centre National D’Etudes Veterinaires et Alimentaires (CNEVA)
CNEVA Nancy
Tel. (33-3) 83298950
Domain de Pixerecourt
Fax. (33-3) 83298959
B.P. 9, F-54220, Malzeville
FRANCE

28.

Association Francophone de Veterinaires de Faune Sauvage
47 ave. Jean Mermoz
69008 Lyon
FRANCE

29.

Association Francaise des Veterinaires de Parcs Zoologiques (AFVPZ)
Association loi 1901, Siege social
Parc Zoologique de Paris
53 avenue de St. Maurice
75012 Paris
FRANCE

30.

Institute of Biology and Wildlife Research
P.O. Box 1103
Alfred-Kowalke-Strasse 17
D-10252, Berlin
GERMANY

31.

Universitat Gottingen
Institut fur Wildbiologie und Jagdkunde
Busgeweg, 3
3400 Gottingen
GERMANY

32.

Tierarztliche Hochschule Hannover
Bischofsholer Damm 15

81
3000 Hannover 1
GERMANY
33.

34.

Wildlife Institute of India
P.O. Box 18, Chander Bani
Dehra Dun, Uttar Pradesh
INDIA

Tel. (91-135) 640 112
vetwilde@yaho.com

College of Veterinary and Animal Sciences
Mannuthy, Trichuar District
Kerala 680651
INDIA

Tel. (91-487) 22344
vet@kau.ren.nic.in

34.

Zoo Outreach Organisation
P.O. Box 1683 – PEELAMEDU
Coimbatore 641 004
INDIA

35.

Wildlife and Fisheries Bureau
Department of the Environment
P.O. Box 5181, Code 15875
Tehran, I. R. of IRAN

Tel. (9821) 890 1261
Fax. (9821) 890 8275

36.

Food and Agriculture Organisation of the United Nations (FAO)
Animal Health Service
Animal Production and Health Division
Tel. (39-6)-570 54798
Viale delle Terme di Caracala
Fax. (39-6) 570 53023
00100 Rome, Italy
empres-livestock@fao.org

37.

Societa Italiana di Ecopatologia della Fauna
Fac. di Med. Veterinaria
Universita di Torino
Via Nizza 52 – 10126 Torino
ITALY

38.

Japanese Association of Wildlife Veterinarians
Kobe Municipal Oji Zoo
3-1 Oji-Cho, Nada-ku
Kobe 657, JAPAN

39.

Wildlife Rescue Veterinary Association
Suda Animal Hospital
4-30-7 Minamidaira Hino-City
191 Tokyo, JAPAN

40.

IUCN SSC Reintroduction Specialist Group (RSG)
C/o African Wildlife Foundation
P.O. Box 1897
Nairobi, KENYA

Tel. (254-2) 710367
Psoorae@awfke.org
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41.

Laboratory of Virology
Erasmus University
Dr MolewaterPlein 50
300 DR Rotterdam
THE NETHERLANDS

42.

Etosha Ecological Institute
P.O. Box Okaukuejo
via Outjo
NAMIBIA

43.

Ministry of Agriculture and Fisheries
P.O. Box 2526
Wellington
NEW ZEALAND

44.

Faculty of Veterinary Science
Massey University
Palmerston North]
NEW ZEALAND

45.

All-Russian Research Institute of Nature Conservation
Wildlife Health Center
VN11 Priroda
Sadki-Znamenskoye
Moscow 11362
RUSSIA

46.

King Khalid Wildlife Research Center
Thumamah
P.O. Box 61681
Riyadh 11575
KINGDOM OF SAUDI ARABIA

47.

National Wildlife Research Center
P.O. Box 1086
Taif
KINGDOM OF SAUDI ARABIA

48.

Departmento de Patologia Animal
Facultade de Veterinaria
Miguel Servet 177
E-50013 Zaragoza
SPAIN

49.

ARC-Onderstepoort Veterinary Institute
Private Bag X5
Onderstepoort 0110

Tel. (31-10) 408 8066
Fax. (31-10) 436 5145
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REPUBLIC OF SOUTH AFRICA
50.

Faculty of Veterinary Science
Wildlife Diseases
University of Pretoria
Onderstepoort 0110
REPUBLIC OF SOUTH AFRICA

51.

State Veterinary Laboratory
P.O. Box 12
Skukuza 1350
REPUBLIC OF SOUTH AFRICA

52.

South African Veterinary Association Wildlife Group
P.O. Box 12900
Onderstepoort 0110
REPUBLIC OF SOUTH AFRICA

53.

National Veterinary Institute
Division of Wildlife Diseases
P.O. Box 7073
S-750 07 Uppsala
SWEDEN

54.

World Health Organisation (WHO)
1211 Geneva 27
SWITZERLAND

51.

European Association of Zoo and Wildlife Veterinarians (EAZWV)
C/o Swiss Federal Veterinary Office
CH-3003, Berne
SWITZERLAND

52.

Untersuchungsstelle fur Wildtirkrankheiten
Institut fur Tierpathologie
Langgass-Strasse 122
CH-3012, Berne
SWITZERLAND

53.

Swiss Association for Wildlife, Zoo Animal
And Exotic Pet Medicine
Veterinary Faculty, University of Zurich
Winterthurerstrasse 260
CH-8057, Zurich
SWITZERLAND

54.

Serengeti Research Institute (SRI)
P.O. Box 661
Arusha

84
TANZANIA
55.

Wildlife Research Laboratory
Dept. of Zoology
Kasetsart University
Bangkhen, Bangkok 10900
THAILAND

56.

Animal Diseases Central Research Institute
Pendik-Ankara
TURKEY

57.

FAO World Reference Laboratory for Rinderpest
Institute of Animal Health
Pirbright Laboratory
Tel.(44-1483) 232 441
Ash Road, Pirbright
Fax.(44-1483) 232 448
Woking, Surrey GU24 0NF
ann.boddy@bbsrc.ac.uk
UNITED KINGDOM

58.

World Association of Wildlife Veterinarians (WAWV)
16 Cranlome Road
Ballygawley
Co. Tyrone BT70 2HS
Northern Ireland
UNITED KINGDOM

59.

The Zoological Society of London (ZSL)
Institute of Zoology
Regent’s Park
London NW1 R4Y
UNITED KINGDOM

60.

The Game Conservancy
Crubenmore Lodge
Newtonmore
Invernessshire PH20 1BE
Scotland, UNITED KINGDOM

61.

MAFF Central Science Laboratory
Woodchester Park
Nympsfield
Stonehouse, Glos. GL10 3UJ
UNITED KINGDOM

62.

MAFF Central Veterinary Laboratory
New Haw
Weybridge, Surrey KT15 3NF
UNITED KINGDOM

Tel. (44-207) 722 3333
Fax. (44-207) 483 4436
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63.

Wildfowl and Wetlands Trust
Slimbridge
Gloucester
UNITED KINGDOM

64.

Veterinary Invertebrates Society
7 Cheveney Walk
Bromley, Kent BR2 0XZ
UNITED KINGDOM

65.

British Wildlife Health Association
The Oceans, Pontesbury Hill
Pontesbury
Shrewsbury, Shropshire SY5 0YH
UNITED KINGDOM

66.

Care for the Wild
Ashfolds
Rusper
West Sussex RH12 4QX
UNITED KINGDOM

Tel. (44-1293) 871596
Fax. (44-1293) 871022
cftw@fastnet.co.uk

67.

University of Edinburgh Veterinary Field Station
Easterbush
Midlothian EH25 9RG
Scotland, UNITED KINGDOM

68.

British Veterinary Camelid Society
Middlefield House
By Dumfries DG1 3SF
Scotland, UNITED KINGDOM

Tel: (44-1387) 750 351

69.

British Veterinary Zoological Society
7 Bridgewater Mews
Pandy
Wrexham LL2 8EQ
UNITED KINGDOM

Tel. (44-1978) 852 065
dglyon9@aol.com

70.

Centers for Disease Control and Prevention (CDC)
Atlanta, Ga. 30333
UNITED STATES OF AMERICA

71.

National Wildlife Research Center (NWRC)
6006 Schroeder Road
Madison, WI 5371
UNITED STATES OF AMERICA

72.

United States Dept. of Agriculture (USDA)
National Veterinary Services Laboratories

Tel. 1 (515) 239 8505
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P.O. Box 844
Ames, Iowa 50010
UNITED STATES OF AMERICA
73.

American Zoo and Aquarium Association (AZA)
Conservation and Science Office
8403 Colesville Road, Suite 710
Silver Spring, MD. 20910-3314
UNITED STATES OF AMERICA

74.

Wildlife Disease Association (WDA)
P.O. Box 1897
Lawrence, KS. 66044-8897
UNITED STATES OF AMERICA

75.

American Association of Zoo Veterinarians (AAZV)
1 North Pennell Road
Media, PA. 19063
UNITED STATES OF AMERICA

76.

American Association of Wildlife Veterinarians (AAWV)
C/o Southeastern Cooperative Wildlife Disease Study
College of Veterinary Medicine
University of Georgia
Athens, GA. 30602-7393
UNITED STATES OF AMERICA

77.

Association of Amphibian and Reptilian Veterinarians
Gladys Porter Zoo
500 Ringgold Street
Brownsville, TX 78520
UNITED STATES OF AMERICA

78.

Association of Avian Veterinarians
Central Office
P.O. Box 811720
Boca Raton
FL. 33481
UNITED STATES OF AMERICA

79.

International Wildlife Rehabilitation Council
4437 Central Place, Suite B4
Suisun, CA. 94585
UNITED STATES OF AMERICA

80.

IUCN SSC Veterinary Specialist Group (VSG)
2440 Virginia Avenue, N.W.
9448
Apt. D-1105

Tel. 1 (301) 562 0777
Fax. 1 (301) 562 0888

Tel./Fax
dinton@aol.com

1(202)

331
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Washington, D.C. 20037
UNITED STATES OF AMERICA
81.

Veterinary Services Unit
CDFG-OSPR
1701 Nimbus Road, Suite D
Rancho Cordova, CA. 7567
UNITED STATES OF AMERICA

82.

Wyoming Diagnostic Laboratory
Dept. of Veterinary Science
University of Wyoming
Laramie, WY 82070
UNITED STATES OF AMERICA

83.

Texas Veterinary Medical Diagnostics
College Station
TX. 77843
UNITED STATES OF AMERICA

84.

Wildlife Unit
Veterinary Research Laboratory
P.O. Box 8101
Causeway, Harare
ZIMBABWE

85.

Faculty of Veterinary Science
University of Zimbabwe
P.O. Box MP167
Mount Pleasant, Harare
ZIMBABWE
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